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Saccharomyces cerevisiae –hiiva on lupaava organismi vasta-aineiden tuotantoon.
Kuitenkin toistaiseksi saanto on vähäistä, joten meneillään oleva tutkimus keskittyy
tuotannon parantamiseen. Plasmasolut sen sijaan ovat hyvin tehokkaita vasta-
aineiden tuottajia, joten tämän työn tarkoituksena oli hyödyntää plasmasolujen
geenien rikastumisanalyysistä saatua tietoa valittaessa geenejä, mitä muokata
vasta-aineita tuottavassa S. cerevisiae –hiivassa.
Rikastusmisanalyysissä tutkittiin transkriptomiikkadataa neljästä eri tutkimuk-
sesta. Data koostui B-solujen ja plasmasolujen transkriptioista, ja se oli jaettu
yhdeksään alaosioon. Tuloksena oli yhteensä 142 rikastunuttua biologista termiä,
joista seitsemästä tutkittiin tarkemmin, mistä geeneistä ne koostuivat. Rikastumi-
sanalyysissä löydetyistä geeneistä neljä, SBH1, GPD2, TRX1 ja TRX2, valittiin
vaimennettavaksi ja yliekspressoitaviksi vasta-aineita tuottavassa hiivassa. Vasta-
ainetuoton tulokset analysoitiin ELISAlla.
In vivo – kokeissa TRX2-geenin yliekspressio paransi parhaiten vasta-ainetuottoa,
mutta kontrastina sille TRX1-geenin yliekspressio huononsi vasta-aineen tuotantoa.
SBH1-geenin yliekspressio antoi ristiriitaisia tuloksia eri kasvatusolosuhteissa, ja sen
vaimentaminen ei vaikuttanut vasta-ainetuottoon. GPD2-geenin vaimentaminen
paransi suhteellista vasta-ainetuotantoa.
Tämän työn tulokset näyttävät, että rikastumisanalyysin ja laboratoriokokeiden
yhdistäminen on yksi strategia hiivan vasta-ainetuoton parantamiseen.
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1 Introduction
Antibody fragments and monoclonal antibodies (mAbs) count currently as the
most important and fastest growing class of biopharmaceutical products, i.e. prod-
ucts which are nucleic-acid, cell, or tissue-based, or recombinant therapeutic pro-
teins.(Spadiut et al., 2014; Walsh, 2010). In 2013, the global sales of biopharmaceu-
ticals was estimated to reach US$140 billion per year, which is larger than the gross
domestic product (GDP) of three quarters of countries listed in the GDP database
of the World Bank (Walsh, 2014).
Several biopharmaceuticals are produced in the yeast Saccharomyces cerevisiae,
and it was the first yeast used in the recombinant protein production. Yeast is an
attractive host for the production of antibody fragments and mAbs, due to its status
as “generally recognized as safe” (GRAS), well-known biochemical and molecular
properties plus manipulation techniques, the ease of cultivation, and the stability
of its expression system. However, its secretory capacity and productivity is still
low. The efficient production of antibodies is hindered by inefficient trafficking in
the secretory pathway and misfolding in the endoplasmic reticulum (ER). Current
research is focused on improving the production yield of S. cerevisiae (Berlec and
Strukelj, 2013; Spadiut et al., 2014).
One possible way to improve the secretion of antibodies in S. cerevisiae is to
look into nature and see how the antibody-secreting plasma cells function. This can
be done by enrichment analysis, which is a high-throughput method for identifying
which biological functions play a key role in a given biological phenomenon. If a
certain process is relevant in plasma cells, it is likely to be found as enriched by
statistical methods when going through transcriptomics data (Huang et al., 2009).
The genes involved in this process can then be modified in antibody-secreting S.
cerevisiae in order to improve its production yield.
The target of this thesis was to find out how the enriched genes of plasma
cells affected the antibody production of Saccharomyces cerevisiae. The aim of
the enrichment analysis was to find out which biological processes and molecular
functions have a significant role in the functioning of plasma cells, and which genes
contribute to these enriched functions. Four of the enriched genes were selected for
further testing. They were both overexpressed and knocked out in antibody-secreting
S. cerevisiae in order to see whether they would enhance antibody secretion also in
yeast.
This thesis consists of a literature part and experimental part. The literature part
covers an overview of three main topics regarding this thesis. Plasma cell development
and properties of antibodies are introduced. Antibody production in S. cerevisiae
and its challenges are presented. Finally, transcriptomics and enrichment analysis are
described. In the experimental part, the used materials and methods are described.
The results are divided into two parts, the results of the enrichment analysis are
described first, and the second part discusses the results of the overexpression and
knockout studies on S. cerevisiae.
22 Plasma cells
Immunity means the ability of the body to defend itself against specific pathogens such
as bacteria, viruses, toxins, and foreign tissue. Antigens are substances recognized as
foreign, and they provoke the immune response. The immune system is divided into
innate and adaptive immune system. The innate immune system is responsible for
rapid response to an antigen, and the adaptive system forms a specific response to a
previously encountered pathogen. Both immune systems function by first recognizing
antigen and then working on eliminating or neutralizing the invader. The innate
immune system recognizes structural elements, like certain glycolipids, that are
present in many pathogens but absent from the host organism. The adaptive immune
system is able to form over 108 distinct antibodies which recognize specific antigens.
Due to the specificity of the adaptive immune system, the second encounter with an
antigen usually elicits more rapid and vigorous response (Berg et al., 2007; Tortora
and Derrickson, 2006).
In the adaptive immune system, there are two parallel and interrelated systems:
humoral and cellular immune responses. In the cellular response, cytotoxic T lym-
phocytes (killer T cells) kill cells invaded by the pathogen. In the humoral response,
antibodies travel usually in lymph and blood to the antigen invasion site, where they
function as recognition elements which bind to foreign molecules and act as markers
that signal foreign invasion (Berg et al., 2007; Tortora and Derrickson, 2006).
Plasma cells are antibody-secreting cells that play a key role in the humoral
immunity response. They develop from B cells, which are activated by antigens, after
which they proliferate and differentiate into plasma cells or activated T-cells. After
exposure to an antigen, plasma cells secrete antibodies until the cells themselves die
(Berg et al., 2007; Tortora and Derrickson, 2006). Plasma cells secrete antibodies
but do not proliferate, unlike some fractions of the proliferating B cells, called
plasmablasts, which secrete measurable amounts of antibody (Oracki et al., 2010).
2.1 Antibodies
The function of antibodies is to bind to antigens, and to be a facilitator of their
removal from the body. Generally an antibody recognizes only a certain small part,
an epitope, of an antigen, for instance certain amino acids of a viral coat protein
(Janeway et al., 2001).
Antibodies are also called immunoglobulins (Igs), since they belong to a group of
glycoproteins called globulins. Most antibodies comprise four polypeptide chains,
of which two are called heavy (H) chains, and the other two light (L) chains. Both
heavy and light chains are identical with their respective counterpart. Heavy chains
consist of about 450 amino acids, and they have short carbohydrate chains attached
to them. Light chains consist of about 220 amino acids, and each one is connected
to a heavy chain by a disulfide bond (Tortora and Derrickson, 2006). There are two
types of light chains, λ and κ (Berg et al., 2007). The heavy chains of IgG are also
connected to each other via two disulphide bonds that reside in the midregion of the
heavy chains. This area called hinge region is very flexible, and thus the antibody can
3be shaped either T or Y like by bending the hinge region. The antigen-binding sites,
that recognize and attach to specific antigens, are located at the tips of the heavy
and light chains called the variable (V) regions. The bending of the hinge region
allows the antigen-binding sites to attach to two identical epitopes that are apart
from each other. The region adjacent to the variable region is called the constant
(C) region, and the structure of the heavy chains in this region is used as a basis
for distinguishing the five different antibody classes (Tortora and Derrickson, 2006).
The structure of an antibody molecule is illustrated in picture 1.
Figure 1: Antibody molecule structure. Pink parts are light chains; yellow and purple
parts heavy chains. VH and VL refer to respective variable regions of the heavy
and light chains, and parts CH1-3 make up the constant region with their identical
counterparts (Janeway et al., 2001).
The domains of an antibody have many common sequence features, and they
adopt a common structure, the immunoglobulin fold, which is also found in many
other proteins playing key functions in the immune system. The immunoglobulin
fold consists of a pair of β sheets, built of antiparallel β strands surrounding a
central hydrophobic core. The sheets are connected by a disulphide bridge. Three
hypervariable loops, called that because the hypervariable sequence of an antibody
is located there, forming a potential binding surface reside at the surface near the
N terminus. The C and N terminuses of immunoglobulin fold are at the opposite
ends of the immunoglobulin fold, allowing them to form chains, like the the light
and heavy chains of an antibody, by being strung together (Berg et al., 2007).
The five different antibody classes are IgM, IgD, IgG, IgA, and IgE, and they
have heavy chain names corresponding to their respective lower-case Greek letter
(µ, δ,γ,α, and , respectively) (Janeway et al., 2001). IgG is the most abundant one,
about 80% of all antibodies in the blood belong to this class. In addition to blood,
it is also found in lymph and the intestines. It enhances phagocytosis, neutralizes
toxins, and triggers the complement system, which is a defensive system made of a
set of proteins that destroy microbes collectively. IgA accounts for about 10-15%
of antibodies in blood, however it is mainly found in sweat, saliva, tears, mucus,
breast milk, and gastrointestinal secretions. It provides localized protection against
viruses and bacteria on mucous membranes. IgM is present in blood and lymph, it
4comprises about 5-10% of antibodies in blood. It activates the complement system,
and causes agglutination and lysis of microbes. It is the first one to be secreted by
plasma cells, thus its’ presence is an indicator of a recent invasion. IgD is involved
in the activation of B cells, and it is found mainly on their surfaces. It accounts
only for about 0.2% of antibodies in blood. IgE resides in mast cells and basophils,
and it is involved in allergic reactions and in providing protection against parasitic
worms. Less than 0.1% of antibodies in blood are IgE. IgG, IgD, and IgE occur only
as monomers, IgA can also occur as dimers, and IgM occur in pentamers (Tortora
and Derrickson, 2006).
2.2 Development of plasma cells
Plasma cell development begins by B cell activation by the antigen, which occurs
when an antigen binds to B cell receptors (BCRs) on the surface of the B cell. BCRs
are monomers of IgM, and each B cell has its own specific type of IgM expressed
on its surface. The plasma cells developing from a certain B cell will all secrete
antibodies chemically similar to the IgM of the B cell. Different antigens stimulate
different B cells to develop into plasma cells, and thus the body is able to form an
immune response against a large variety of pathogens (Berg et al., 2007; Tortora and
Derrickson, 2006).
The activated B cells process the antigen by taking it into the cell and break-
ing it down into peptide fragments. These fragments are combined with major
histocompatibility complex class II (MHC-II) proteins, which function mainly as
antigen-presenting molecules. MHC-II proteins present the antigens to CD4 cell-
surface proteins of helper T cells, which deliver the costimulation needed for B cell
proliferation and differentiation(Berg et al., 2007; Madigan et al., 2009; Tortora and
Derrickson, 2006). A single MHC protein can bind to peptides sharing a unique
peptide motif, for instance a phenylalanine at position 5 and a leucine at position
8. As long as the peptide has the correct residues, the MHC protein can bind to it.
Thus all antigens will have at least few peptides forming a peptide motif that will be
bound by MHC proteins (Madigan et al., 2009).
2.2.1 Germinal center reaction
The process of selecting which cells develop and reproduce is critical to the immune
system. The immune response is based on selecting the cells expressing molecules
that are effective against a particular foreign invader (Berg et al., 2007). This
selection is done in the germinal centers, which are the sites where B cells develop
into high-affinity antibody-secreting plasma cells and memory B cells (Victora and
Nussenzweig, 2012).
Germinal centers (GCs) are areas of high mitotic activity in lymph nodes. They
can be divided into two zones, dark and light one. The dark zone appears dark in light
microscopy, as it is almost entirely made of B cells having a high nucleus-to-cytoplasm
ratio. The light zone consists of B cells interspersed among a network of follicular
dendritic cells that make it appear lighter. It also contains T cells expressing surface
5proteins CD8 and CD4 on their surface. The suggested model for germinal center
reaction by Victora and Nussenzweig (2012) is illustrated in figure 2 (Victora and
Nussenzweig, 2012).
6Figure 2: Proposed model of GC reaction by Victora and Nussenzweig (2012). a)
Before entering the reaction, B cells compete for a limiting number of T cells, and
only the ones that have the highest affinity are selected for the GC reaction. b) In the
dark zone, cells proliferate and undergo somatic hypermutation, with the aid of AID
and Polη enzymes. High expression of chemokine receptor CXCR4 maintains these
cells in the dark zone. Cells with impaired BCR expression (∅ BCR) die due to the
lack of a BCR signal. After one or more cycles of division and somatic hypermutation,
B cells migrate towards the light zone. This process involves the upregulation of
chemokine receptor CXCR5. c) B cells interact with antigen in immune complexes
on follicular dendritic cells (FCDs). At this stage, B cells that have very low or zero
affinity for antigen may also die due to the missing BCR signal. At this point, antigen
signals are not limiting, and all B cells that transit to the light zone upregulate CD83
and CD86. The level of peptide-MHC (pMHC, red rectangles) on the B cell surface
is determined by BCR affinity. d) B cells present antigen to T helper cells, which
amount is limited. B cells that have higher pMHC are preferred in this competitive
process. B cells successfully interacting with T cells have then three different fates.
They may re-enter the dark zone with upregulation of CXCR4, and undergo further
cycles of proliferation and hypermutation. They can become memory B cells. They
can also exit the GC and become plasma cells. This third option is likely for cells that
have high affinity or pMHC density. In the picture the width of an arrow represents
the proportion of cells moving towards that path. Dashed arrows represent events
for which data was found to be inconclusive (Victora and Nussenzweig, 2012).
7Before returning to the light zone, B cells undergo a variable number of divisions
in the dark zone. It has been shown in a study by Gitlin et al. (2014) that the
increased cell division is associated with increased somatic hypermutation and higher
immunoglobulin affinity. Therefore the high-affinity germinal center B cells are able
to outcompete their low-affinity counterparts by diving greater number of times and
capturing more antigen during each cycle (Gitlin et al., 2014).
2.2.2 Factors promoting plasma cell fate
B-lymphocyte induced maturation protein (Blimp1), transcription factor XBP1 (X-
box binding protein 1), and interferon regulatory factor-4 (IRF4) are three main
factors promoting the plasma cell fate in the germinal center reaction (Nutt et al.,
2011).
IRF4 has been found in a genome-wide expression analysis by Sciammas et al.
(2006) to regulate the induction of the entire Blimp1-dependent plasma cell develop-
ment. B cell lacking IRF4 were severely compromised for class-switch recombination
and plasma cell generation, because of their failure to induce properly the expres-
sion of genes encoding AID (activation-induced cytidine deaminase) and Blimp1,
respectively. Their results suggest that the graded expression of IRF4 promotes the
transition of a germinal center B cell to plasma cell (Sciammas et al., 2006). Similar
results were obtained by Klein et al. (2006), who generated mice in which the gene
encoding IRF4 could be conditionally deleted in germinal center B cells and the fate
of the cells having the deletion could be monitored in vivo. They found that the
mice having the deletion lacked post-germinal center plasma cells and were unable
to differentiate memory B cells into plasma cells. It was found that plasma cell
differentiation needed IRF4 and Blimp1, both acting upstream of XBP1. It was also
found that class-switch recombination was dependent of IRF4 (Klein et al., 2006).
Blimp1 is a zinc-finger containing transcription factor regulating a vast amount
of genes inducing the differentiation of multiple cell types. It is required for B
cell development into fully mature plasma cells (Shapiro-Shelef et al., 2003). It
has been found by Lin et al. (2002) to repress the gene Pax-5 encoding the B-cell
lineage-specific activator protein (BSAP). BSAP is critical for the cells committing
into B-cell lineage. Lin et al. (2002) found that Blimp1 bound a site on the Pax-5
promoter, and repressed the promoter in a binding-site-dependent manner. This
repression was required for the plasma cell development, and it was concluded that
the repression of Pax-5 by Blimp1 is critical for the development of plasma cells
(Lin et al., 2002). Shaffer et al. (2002) found that the introduction of Blimp1 into B
cells blocked a large set of genes important for B cell receptor signalling, germinal
center B cell function and proliferation. At the same time it allowed the expression
of important plasma cell genes, including the transcription factor XBP1. (Shaffer
et al., 2002) In a study by Shaffer et al. (2004), it was found that Blimp1-deficient B
cells did not upregulate Xbp1 or most other genes specific to plasma cells. Blimp1
was found to repress genes which in turn encode the repressors of plasma cell genes.
It was also required for the maximal induction of immunoglobulin genes (Shaffer
et al., 2004). It can be concluded that Blimp1 functions as a master regulator of
8plasma cell differentiation by enhancing immunoglobulin expression, shutting down
unnecessary cellular processes, and facilitating the induction of XBP1 (Brewer and
Hendershot, 2005).
XBP1 is required for the terminal differentiation of plasma cells (Reimold et al.,
2001). Only the spliced form of XBP1, XBP1(S), is able to efficiently activate the un-
folded protein response. It is spliced by serine/threonine-protein kinase/endoribonuclease
IRE1. Activating transcription factor 6 (ATF6) induces the XBP1 and ER chaperone
genes via direct binding to ER stress-responsive element (ERSE) (Yoshida et al.,
2001). It has been found to coordinate diverse changes in the cellular functioning
and structure leading to secretory cells in a gene expression profiling study by Shaffer
et al. (2004). In the study its expression induced a vast spectrum of genes involved
in the secretory pathway and the physical expansion of the ER. They also found that
the expression of XBP1 increased cell size, lysosome content, mitochondrial function
and mass, ribosome numbers, and total protein synthesis. Its overexpression led to
the overexpression of genes encoding components in the secretory pathway such as
proteins targeting and translocating nascent polypeptides into the ER, chaperones
and their cofactors promoting protein folding, oxidoreductases regulating protein
folding, glycosylation enzymes, and vesicular trafficking regulators. In the same
study it was concluded that XBP1 acted downstream of Blimp1, since almost all of
the genes requiring XBP1 required also Blimp1, but a number of plasma cell genes
required only Blimp1 (Shaffer et al., 2004).
2.2.3 Unfolded protein response
Unfolded protein response (UPR) is a multidimensional signalling pathway regulating
the expression of ER resident proteins and lipids, translation, the cell cycle, and
apoptosis. The components of UPR also regulate cell differentiation and are involved
in innate immunity. UPR is triggered by the accumulation of unfolded proteins in
the ER (Brewer and Hendershot, 2005; Hetz, 2012; Masciarelli and Sitia, 2008). It
aims to reduce the stress inflicted into the ER from the unfolded protein load by
mechanisms like the expansion of the membrane of ER, the attenuation of protein
uptake into the ER, and the synthetisation of molecules involved in protein folding
and quality control. If the homeostasis is not restored, apoptosis is triggered by the
UPR (Hetz, 2012).
UPR has three branches that are initiated by different sensors in response to
ER stress. These sensors are inositol-requiring protein 1α (IRE1α), protein kinase
RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6). They
govern together the expression of a vast range of target genes, which are partly
overlapping. The proteins encoded by the target genes modulate the adaptation to
stress or induce apoptosis (Hetz, 2012).
IRE1α dimerizes and autophosphorylates, which trigger its RNase activity in
order to splice the RNA encoding transcription factor XBP1 into its active spliced
form XBP1(S). This branch of UPR controls via the active form of XBP1 the genes
encoding proteins involved in protein folding and quality control, ER-associated
degradation (ERAD), and phospholipid synthesis (Hetz, 2012).
9The second branch of UPR, triggered by the activation of PERK, is involved
in the attenuation of protein synthesis. The initiation factor eukaryotic translation
initiator factor 2α (eIF2α) is phosphorylated by PERK, and the phosphorylation
allows the translation of ATF4 mRNA encoding a transcription factor which controls
the transcription of genes involved in apoptosis, autophagy, antioxidant responses,
and amino acid metabolism (Hetz, 2012).
The third branch of UPR is activated by ATF6, which is transported to the
Golgi apparatus, where proteases site 1 protease (S1P) and site 2 protease (S2P)
release its cytosolic domain fragment, ATF6f. This fragment contols XBP1 and the
upregulation of genes encoding components of ERAD (Hetz, 2012).
2.2.4 Preparation for protein production
Antibodies and other secretory proteins undergo post-translational modifications in
the endoplasmic reticulum (ER) to attain their three-dimensional structure. These
modifications including glycosylation, disulphide bond formation, and cleavage of the
signal sequences, are catalyzed by various chaperones and enzymes (Masciarelli and
Sitia, 2008). The differentiation process remodels B cells into antibody-producing
‘cell factories’ that are built, equipped, and managed for optimal antibody synthesis
and secretion. During differentiation, the ER expands into an elaborate network
extending thoughout the cytoplasm. The expansion of the ER is complemented by
the enlargement of the Golgi complex. The changes needed for converting a B cell
into a plasma cell are illustrated in figure 3 (Brewer and Hendershot, 2005). Massive
antibody secretion imposes metabolic requirements for the cell, particularly regarding
amino acid uptake, ATP synthesis, and redox homeostasis (Masciarelli and Sitia,
2008). Thus the secretory organelles, particularly the ER, are larger in plasma cells
than in B cells (Romijn et al., 2005).
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Figure 3: Building an antibody factory requires dramatic remodelling of the cell.
The changes include the building of the secretory apparatus, the equipment of the
cell with larger amounts of ribosomal subunits, mitochondria to provide energy,
and components of metabolic processes and amino acid synthesis, the management
of the product quality by increasing the amount of folding enzymes, chaperones,
and components of the quality control system, and finally the upregulation of im-
munoglobulin genes. Blimp1 regulates all of the processes, including the upregulation
of XBP1. XBP1 induces proteins involved in the preparation for antibody secretion.
Ire1 is needed for remodelling XBP1 into its spliced form. Adapted from Brewer and
Hendershot (2005).
Romijn et al. (2005) studied the expression patterns of proteins during plasma cell
development. They found that ER-resident proteins were continuously upregulated
during the differentiation from B cell to plasma cell. Soon after the activation
of naïve B cell, proteins needed for protein production and energy supply were
upregulated. Many ER-resident proteins involved in protein folding were upregulated.
For instance, protein disulphide isomerase (PDI) was constantly upregulated, and
binding immunoglobulin protein (BiP, a molecular chaperone promoting proper
protein maturation) showed a transient peak in expression at the first day after B
cell activation. Ribosomal subunits, and other proteins involved in translation, were
initially strongly upregulated. Proteins involved in the immune system, like Ig light
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and heavy chain proteins, were initially downregulated, but upregulated again at
later stages of plasma cell differentiation. The production of IgM started when the
cell’s secretory capacity has increased. These findings show that the B cells have to
first prepare themselves for the large scale production of antibodies (Romijn et al.,
2005). Plasma cells are able to secrete antibodies at the rate of up to 108 IgG, IgA,
or IgM molecules per cell per hour (Hibi and Dosch, 1986).
2.2.5 Folding of antibodies
The folding of the heavy and light chains of antibodies begin before the translation
of the polypeptide chain is completed. In most cases, the heavy chain dimers are first
assembled, and the light chains are added to the dimers covalently via a disulphide
bond (Feige et al., 2010). Feige et al. (2010) have illustrated the folding and assembly
of an IgG molecule. This is shown in picture 4. The steps are probably true also for
other classes of Ig molecules.
Figure 4: The folding and assembly of an IgG molecule. Folding, glycosylation,
and the formation of disulphide bridges starts cotranslationally in the ER. Most
of the IgG domains interact with BiP (shown in red) during folding. Most variable
domains and all constant domains besides CH1 fold autonomously. The completion
of folding CH3 induces heavy chain (HC) dimerization solidified by disulphide bridges
residing in the hinge region. CH1 domain remains bound to BiP unfolded until the
completed light chain (LC) replaces BiP and CL induces its folding. Disulphide
bridge between the light and heavy chains forms once the CH1 domain is folded, and
the IgG molecule is ready to be secreted (Feige et al., 2010).
In their review, Feige et al. (2010) have grouped Ig domains into three categories
on the basis of their folding. In the first category, domains are able to fold to a
monomeric state autonomously. The folding is guided by an internal disulphide
bridge. A major intermediate on the pathway has a proline residue between two
strands that needs to isomerize from its non-native trans state to cis state before
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folding is able to proceed. CL and CH2 domains fold this way. The second category,
which holds for CH3 domain of IgG, folds slower than the first category domains and
forms an obligate homodimer. It folds via two intermediates, where the second one
is formed after a critical proline residue in the first one isomerizes to its native cis
state. The second intermediate is able to dimerize and complete folding. The third
category is the template-assisted folding of the CH1 domain. The unfolded domain
interacts with the CL domain in the intact antibody, which induces its folding. The
prerequisite for folding is not an intramolecular disulphide bridge, like in the other
two categories, but a covalent linkage of two cysteine residues (Feige et al., 2010).
The same mechanisms which allow the generation of diverse antibodies and the
affinity maturation of the immune system also increase the possibility of secreting
an antibody which isn’t able to fold or assemble correctly. This could affect the
functioning of the immune system. Therefore, plasma cells and other B cell lineage
cells depend heavily of the quality-control system of the ER in order to ensure the
transportation to the cell surface of only correctly assembled antibody molecules
(Feige et al., 2010).
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3 Saccharomyces cerevisiae in antibody production
Yeasts are unicellular eukaryotes that are one of the simplest model organisms.
Their sub-cellular organization containing a nucleus, mitochondria, endoplasmic
reticulum (ER), Golgi apparatus, secretory vesicles, vacuoles, and microbodies is
similar to higher eukaryotes. Saccharomyces cerevisiae, or baker’s yeast, has been
used in human diet for centuries and has been accepted as generally recognized as
safe (GRAS). Therefore from the regulatory point of view, it is a good host for
producing recombinant protein products. Its biochemical and molecular properties
and manipulation techniques are also well known (Berlec and Strukelj, 2013).
S. cerevisiae has beneficial characteristics for protein production of both prokary-
otes and eukaryotes. Like prokaryotes, it is able to grow fast in cheap media, and
its genetic manipulation is simple. It has the abilities for folding, disulphide bond
formation, proteolytic processing, and post-translational modifications without car-
boxylation, common with eukaryotes. However, S. cerevisiae can’t reach high cell
densities, and its secretory capacity is limited (Berlec and Strukelj, 2013).
3.1 Engineering of Saccharomyces cerevisiae
The secretory pathway is a common pathway used to complete secreted proteins
and proteins targeted to the plasma membrane and organelles of the endosome
membrane system. Secreted proteins are synthesized on ER-bound ribosomes. They
are co-translationally translocated into the ER lumen, where they attain their native
conformation. After ER, they are transported to the Golgi apparatus by vesicular
transport (Anelli and Sitia, 2008; Idiris et al., 2010). In the Golgi apparatus, the
proteins are further modified, for instance by glycosylation. Transport vesicles carry
the proteins to their destination (Berg et al., 2007).
The production of antibody fragments consisting of the heavy chain variable
domain, VHH fragments, in S. cerevisiae has been obtained by Frenken et al. (2000)
and Thomassen et al. (2002). Frenken et al. (2000) raised in Lama glama VHH
fragments against human chorionic gonadotropin (hCG), and azo-dyes RR6 and
RR120. The highest production level, 9.3 mg/(l ∗OD600) was reached for one of the
hCG antibody fragments, whereas the highest production rate of antibody fragments
against RR6 azo-dye was 3.9 mg/(l ∗OD600). It was found that the secretion rate
varied from 25% to 90% for different antibody fragments. Thomassen et al. (2002)
were able to produce VHH fragments against the RR6 azo-dye in S. cerevisiae. The
efficiency of the secretion correlated with the hydrophobicity of the fragments in a
way that the more hydrophilic fragments were secreted more efficiently. In total 1.3
kg of VHHs were produced in a 15m3 fed-batch fermentation. The obtained specific
production rate during induction was 0.213g/(kg ∗ dryweight) per hour.
The process of protein folding and subsequent secretion involves many interacting
participants. Due to the complexity of the process, modifying the expression level
of one step may limit the rate of another one making it a new bottleneck of the
whole expression system. Possible bottlenecks limiting the protein yield are shown
in figure 5 (Gasser et al., 2008). Factors affecting heterologous protein synthesis
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include co- or post-translational translocation of nascent proteins into the ER, protein
folding and quality control inside the ER, and protein N-glycosylation in the ER
and Golgi apparatus. Protein secretion is also affected by intracellular protein
sorting and trafficking, proteolytic degradation, and stress response for misfolding or
overexpression (Idiris et al., 2010). Folding, glycosylation, disulfide bond formation,
and vesicle trafficking of the secreted protein must all be accomplished, and at the
same time quality control feedback loops must be maintained and cellular homeostasis
should not be disturbed. Each process has to be tuned to a certain state on the basis
of the physical properties of the secreted protein, like size, amount of disulfide bonds,
or hydrophibicity. Because of these demands and the complexity of the cellular
system, it is difficult to engineer a S. cerevisiae strain that could be used for the
production of many different recombinant proteins (Hou et al., 2012).
Figure 5: The secretory pathway of S. cerevisiae and its potential bottlenecks
regarding protein secretion (Idiris et al., 2010).
Current strategies for strain engineering for protein secretion are mainly focused
on four topics (Idiris et al., 2010):
– Engineering of the intracellular protein trafficking pathway, including translo-
cation
– Engineering of protein folding and quality control system in the ER
– Engineering of protein N-glycosylation
– Minimization of post-secretory proteolytic degradation
The research focusing on these four topics is reviewed in this chapter.
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3.1.1 Engineering of translocation
The intracellular trafficking of secretory proteins is initiated with their translocation
into the ER lumen and completed by stepwise vesicular transport. The transport steps
after ER are from ER to Golgi, intra-Golgi, and post-Golgi traffic, respectively. After
the protein is correctly folded in the ER lumen, the trafficking between organelles is
predominantly done by membrane-enclosed transport vesicles. The newly synthesized
proteins are selected and concentrated into distinct vesicle populations, which are
targeted to a specific acceptor compartment. Inefficient traffic or missorting often
results in intracellular retention or accumulation of the target protein for secretion
(Idiris et al., 2010). Different proteins can accumulate in different compartments
(Hou et al., 2012). When optimizing the intracellular vesicle trafficking pathway, it
is important to identify which step is the rate-limiting one (Idiris et al., 2010).
Translocation into ER is determined by the presignal sequence. The presence
of the sequence marks the nascent polypeptide chain as one for crossing the ER
membrane, and its hydrophobicity determines whether the polypeptide chain is
directed to the ER lumen by the signal-recognition particle (SRP) (Ng et al., 1996).
Thus engineering of the signal sequence is a way to affect the translocation. In the
SRP-dependent route, the signal sequence is recognized by the signal-recognition
particle (SRP), which binds to the sequence and the ribosome during translation,
which is then paused. SRP binds to the SRP receptor (SR) on the ER membrane,
and the SRP-SR complex brings the ribosome to the ER membrane, where it docks
with a protein-conducting channel, the translocon. Protein synthesis resumes, and
the growing polypeptide chain passes through Sec61 complex of the translocon into
the ER lumen (Berg et al., 2007). If SRP doesn’t bind strongly enough to the signal
sequence on the polypeptide chain, translation keeps proceeding, and the nascent
polypeptide chain is targeted posttranslationally to the translocon through Sec62/63p
complex. Then, like the polypeptides interacting with SRP, the chain is passed
through Sec61 complex into ER lumen (Ng et al., 1996).
Synthetic leader sequences can be used to overcome problems arising from inef-
ficient processing of pre- or pro-leaders, hyperglycosylation, protein accumulation,
or incorrect trafficking in the secretory pathway. Shusta et al. (1998) used two
different synthetic leader sequences in their study for increasing scFv production in
S. cerevisiae. The first one was a synthetic pre pro region based on a consensus
signal sequence, and the construct was expressed under the control of GAL 1-10
promoter. The second one was a synthetic signal peptide derived from α factor,
expressed under under the control of constitutive GAPDH promoter. The first one
resulted in approximately 6- to 10-fold increases in protein production over low copy
plasmid levels, but after overexpression of Gal4p, which increases transcription from
the GAL 1-10 promoter, the secretion levels dropped due to the oversaturation of
the secretory pathway because of scFv accumulating in an ER-processed pre-Golgi
form. The second one resulted in elevated secretion levels, as described in section
3.1.2 (Shusta et al., 1998).
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3.1.2 Engineering of protein folding in the ER
Possible bottlenecks in the ER are protein misfolding, protein aggregation, unfolded
protein response, and ER-associated protein degradation (see figure 5) (Idiris et al.,
2010). The inability of foreign polypeptides to reach their native conformation
in heterologous host cells usually leads into their prevalence in the insoluble cell
fraction. The cells are driven to a global conformational stress condition by the
abnormally high and non-physiological rates of recombinant protein production and
the abundance of misfolded protein species. By a series of individual physiological
responses the cell aims to restore cellular homeostasis and minimize any toxicity
of misfolded protein species (Gasser et al., 2008). The accumulation of unfolded
or misfolded protein triggers the unfolded protein response (UPR) pathway, which
aims at reducing the ER stress by inducing genes involved in protein folding and
ER-associated protein degradation (ERAD) (Delic et al., 2014a). Idiris et al. (2010)
have reviewed ways to overcome bottlenecks associated with ER, and they have
concluded that overexpressing the genes encoding protein disulfide isomerase (Pdip)
and chaperones like Kar2p, which is the yeast homologue of binding immunoglobulin
protein (BiP) (Rose et al., 1989), which binds to the nascent polypeptide, can be an
effective strategy to increase protein secretion rates in S. cerevisiae.
A study on the effects of Pdip and Kar2p on protein secretion in S. cerevisiae
was done by Xu et al. (2005). The purpose of the study was to examine unfolded
protein response during single-chain antibody fragment (scFv) 4-4-20 expression in S.
cerevisiae. It was found that the overexpression of PDI reduced UPR significantly,
and increased the secretion of scFv. Co-overexpression of both PDI and KAR2
resulted in a significant increase in the secreted levels of scFv. The proposed reason
for the improved expression of scFv was that the overexpression of KAR2 led to
improved translocation of the newly synthesized polypeptide, because it binds to scFv
during its translocation, and the overexpression of PDI resulted in improved folding
rate of scFv. The overexpression of only KAR2 resulted only in modest increase of
scFv secretion, and it was not found to reduce the UPR (Xu et al., 2005). A similar
study was done by Shusta et al. (1998), who studied the effects of co-overexpression
of KAR2 and PDI on production of single-chain antibody fragments in S. cerevisiae.
The co-overexpression resulted in 2-8 fold increase of secretion titers for the studied
five scFvs.
Hackel et al. (2006) produced anti-transferrin receptor single-chain antibody
(OX26 scFv) in S. cerevisiae. They modulated the expression temperature and
overexpressed chaperones in the ER in order to optimize the production yield. The
optimal temperature was found to be +20 °C. Of the chaperones in the ER, the best
results were achieved when co-overexpressing both KAR2 and PDI. The achieved
purified yield of OX26 ScFv was 0.5 mg/l.
Recently, de Ruijter and Frey (2015) researched the effects of disrupting ER
protein quality control on the antibody production in S. cerevisiae. They deleted
individually YOS9, HTM1, UBC7, HRD1, or HRD3 genes. The deletions were
done both with and without disrupting the UPR by deleting IRE1 gene. Antibody
production was slightly increased with the HTM1 deletion. Other deletion strains
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showed decrease in the antibody production, especially the ∆yos9 strain.
Modifying one step in the secretory pathway may lead to rate limitation of the
following one, which may then become the bottleneck of the secretory pathway.
Additionally, the effects of modification are usually protein specific. Thus, the
secretion of different heterologous proteins may be improved by overexpressing
multiple folding helpers and chaperones, or by targeting heterologous or cytosolic
chaperone to the ER lumen (Idiris et al., 2010).
3.1.3 Engineering of protein glycosylation
Protein glycosylation is a significant modification process in the secretory pathway
of S. cerevisiae (Idiris et al., 2010). Initial glycosylation happens already during
translocation. Glycosylation aids folding of the protein, it protects the protein
from proteases, and works as a signal for quality control (Hou et al., 2012). Native
full length monoclonal antibodies are glycosylated during their synthesis, and the
glycosylated constant region stabilizes the antibody and is important for its biological
functioning. Glycosylation of antibodies also impacts their clearance rate from the
body, and incompatibly glycosylated molecules may cause severe immunogenic effects
(Spadiut et al., 2014). Due to the different N -glycan structure, antibodies produced
in S. cerevisiae may cause immunogenic reactions and be cleared rapidly from the
bloodstream after interacting with human mannose receptors (Young and Robinson,
2014).
In yeast, there are two types of glycosylation, N -linked and O-linked. The glycans
involved, N -glycan ad O-glycan are pictured in figure 6. In N -linked glycosylation,
a 14 sugar glycan tree is added to asparagine residue of the recognition sequence
(N-X-S or N-X-T, X is any amino acid except proline). The anchor of the glycan
tree, which is attached to the asparagine residue, is a N -acetylglucosamine. The
ER-resident oligosaccharyl transferase (OST) completes the glycosylation. O-linked
glycosylation occurs at the hydroxyl groups of threonine and serine, and it is catalyzed
by protein O-mannosyltransferases (PMTs). A single mannose is transferred to the
serine/threonine in the ER by PMTs (Hou et al., 2012). These steps happen in
the ER, and they are similar in yeasts and humans. The differences arise from
the glycosyltransferase reactions in the Golgi apparatus. In yeast, the N -glycan
intermediate is modified by several mannosyltransferases that attach more than 50
mannose residues to it (Chiba and Akeboshi, 2009).
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Figure 6: N - and O-glycan structures of S. cerevisiae. Beta linkages are indicated
in the figure, all other linkages are alpha-anomeric. Each linkage is indicated as a
number in the frame on the bottom right. The genes which encode main enzymes
related to yeast-specific modification are represented in bold (Chiba and Akeboshi,
2009).
The differences of N -type glycosylation in S. cerevisiae and mammals are illus-
trated in figure 7, along with a pathway resulting in a human-like N -glycan in S.
cerevisiae engineered by Parsaie Nasab et al. (2013).
A novel synthetic pathway for producing GlcNAc2Man3GlcNAc2, a human-like
N -glycan structure, in S. cerevisiae was recently engineered successfully by Parsaie
Nasab et al. (2013). The structure was confirmed to be present on the secreted
antibody, which was a hybrid human IgG monoclonal antibody directed against hen
egg lysozyme (HyHEL). The strain used was a ∆alg3 ∆alg11 double mutant, where
the N -glycans are not matured to their high-mannose native structure. The deletions
abrogate lipid-linked oligosaccharide (LLO) synthesis, and give rise to lipid-linked
Man3GlcNAc2 structure, which is built up on the cytoplasmic side of the ER in the
mutant strain and flipped by an artificial flippase into the ER lumen, where it is trans-
ferred to the nascent polypeptide by a protozoan oligosaccharyltransferase. Protein-
bound Man3GlcNAc2 is a substrate for human N-acetylglucosaminyltransferases I
and II (GnTI and GnTII) targeted in the Golgi, giving rise to complex N -glycan
GlcNAc2Man3GlcNAc2. The pathway is illustrated in figure 7, along with the
N -glycan pathways in mammals and yeast (Parsaie Nasab et al., 2013).
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Figure 7: The comparison of N -glycan biosynthesis pathways in mammals and
yeast, and of the artificial N -glycan biosynthesis pathway in S. cerevisiae engineered
by Parsaie Nasab et al. (2013). (A) Lipid-linked Man5GlcNAc2 is flipped into
the ER lumen from the cytoplasmic face of the ER membrane. In the ER, it is
further elaborated by luminal mannosyl- and glucosyltransferases. The resulting
structure, Glc3Man9GlcNAc2, is transferred to the nascent polypeptide chain by
oligosaccharyltransferase (OST), and three glucose and one mannose residue are
trimmed. In mammals, mannosidase I (ManI) trims three mannose residues in
the Golgi apparatus, resulting in a substrate for GnTI. A substrate for GnTII is
generated by mannosidase II (ManII), which trims two additional mannose residues.
In S. cerevisiae, a number of mannosyltransferases catalyze the attachment of
mannosyl residues, resulting in highly mannosylated N -glycans. (B) The engineered
pathway as described in the text above. Flc2*p is the artificial flippase, and POT is
protozoan oligosaccharyltransferase. Mannose residues don’t need to be trimmed in
this pathway. Grey circles are mannoses, black circles are glucoses and black squares
are N -acetylglucosamines. The dark grey bar is the ER and light grey bar is the
Golgi apparatus. Adapted from Parsaie Nasab et al. (2013).
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As reviewed by Piirainen et al. (2014), the manipulation of LLO biosynthesis
results often in the accumulation of intermediate structures and hypoglycosylation of
target proteins. The efficiency of N -glycosylation can be improved by the combined
use of protozoan oligosaccharyltransferases and the overexpression of artificial flippase,
which were both done by Parsaie Nasab et al. (2013).
The first reported recombinant S. cerevisiae able to produce an intermediate
N -glycan structure identical with the human structure was engineered by Chiba
et al. (1998). This Man5GlcNAc2, which is a human-like intermediate for hybrid-
and complex-type sugar chains, was engineered by transforming a triple mutant
S. cerevisiae strain lacking three mannosyltransferase activities with an α-1,2-
mannosidase (from Aspergillus saitoi) expression vector (Chiba et al., 1998). The
disrupted genes were OCH1, MNN1, and MNN4,encoding α-1,6-mannosyltransferase,
α-1,3-mannosyltransferase, and a positive regulator for phophomannosyltransferase
(Mnn6p), respectively (Chiba et al., 1998; Nakanishi-shindo et al., 1993).
In contrast to yeast, there are several types of O-glycosylation in mammals. These
include for instance mucin-type (O-linked β-N -acetylgalactosamine: O-GalNAc),
O-linked β-N -acetylglucosamine (O-GlcNAc), O-linked fucose (O-Fuc) and O-linked
glucose (O-Glc). O-GalNAc modifications occur on serine and threonine side chains
of nuclear and cytoplasmic proteins that are involved in almost all cellular functions
(Chiba and Akeboshi, 2009). Mucins and mucin-like glycoproteins are also poten-
tial novel cancer markers, and thus the production of mucin-like glycoproteins for
induction of specific antibodies could be useful (Amano et al., 2008). O-Fuc and
O-Glc are found in several serum proteins. They are post-translational modifications
that are relevant in the early stages of development and are vital for certain proteins’
physiological functions (Chiba and Akeboshi, 2009).
Amano et al. (2008) engineered a strain of S. cerevisiae capable of producing
mucin-type sugar chains. This was done by transforming genes encoding human UDP-
Gal/GalNAc transporter, human ppGalNAc-T1, Bacillus subtilis UDP-Gal/GalNAc
4-epimerase, and Drosophila melanogaster core1 β1-3 GalT into S. cerevisiae. The
resulting yeast was capable of producing a MUC1 like peptide containing O-glycan,
and a mucin-like glycoprotein human podoplanin, which is a platelet-aggregating
factor. The pathway is illustrated in figure 8 (Amano et al., 2008).
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Figure 8: A mucin-type pathway in S. cerevisiae. In the cytosol, UDP-Gal and
UDP-GalNac are synthesized from UDP-Glc and UDP-GlcNAc, respectively, by GalE
protein. UDP-Gal and UDP-GalNAc are transported from the cytosol to the Golgi
lumen by UTG2 protein. In the Golgi, ppGalNAc-Ts and core1 β1-3 GalT transfer
GalNAc and Gal to polypeptides (Amano et al., 2008).
Chigira et al. (2008) used an artificial O-glycosylation pathway in S. cere-
visiae for producing an O-fucosylated epidermal growth factor (EGF) in yeast. The
O-fucosylation system provides a way to produce proteins with homogenous carbohy-
drate chains. These proteins can be used for the production of antibodies recognizing
O-glycosylated EGF domains. The system was engineered via expression of genes
that encode the EGF domain and protein O-fucosyltransferase 1, along with genes
which protein products convert cytoplasmic GDP-mannose to GDP-glucose (Chigira
et al., 2008).
3.1.4 Minimization of post-secretory proteolytic degradation
Host-specific proteases are present in relatively high levels in S. cerevisiae. The
post-secretory degradation of recombinant gene products caused by them is one of
the major problems hindering the effective secretion and purification of heterologous
proteins. The proteases are readily induced by environmental stresses, especially
during high-density fermentation processes. The effects of proteases can be lessened
by either changing the cultivation conditions like temperature or pH, changing
medium composition, adding protease inhibitors, or by genetic manipulation of the
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host proteases. The first three approaches are usually protein specific, and the last
one can be used to develop protease-deficient strains of S. cerevisiae (Idiris et al.,
2010).
An example of successfully manipulating the cultivation conditions was described
in a study by Kang et al. (2000). They researched the secretion of recombinant
human serum albumin (HSA) from the GAL10 promoter in S. cerevisiae. The
target protein underwent rapid degradation, which was accelerated by carbon-source
feeding. It was noted that the degradation correlated closely with the acidification
of extracellular pH, and therefore it was overcome either by buffering the culture
medium above pH 5.0, or by preventing the acidification of medium pH by adding
amino-acid rich supplements to the culture medium. It was concluded that HSA
is very susceptible to pH-dependent proteolysis, which is mediated by cell-bound
proteases whose activity and expression can be affected by modifying the cultivation
medium (Kang et al., 2000).
A study by Jønson et al. (2004) was an example of minimizing proteolytic
degradation by gene distruption. They identified a novel endoprotease in S. cerevisiae,
Cym1p, which is a member of the pitrilysin family. The target peptide tested was pro-
cholecystokinin (proCCK), which is proteolytically processed by Cym1p. Disrupting
the gene coding Cymp1, CYM1, reduced intracellular proteolysis and increased the
secretion of proCCK. It was also found that the disruption increased the secretion of
growth hormone and pro-B-type natriuretic peptide (Jønson et al., 2004).
23
4 Transcriptomics and gene enrichment analysis
Transcriptomics is one of the ’omic’ technologies that aim to adopt a holistic view of
the molecules in a cell, tissue, or organism (Horgan and Kenny, 2011). It studies the
transcriptome, which is the total set of RNA transcripts the genome produces under
certain circumstances in a certain cell (Nature Publishing Group, 2014). According
to Wang et al. (2009), the main aims of transcriptomics are:
– Cataloguing all transcript products, mainly mRNAs, but also small RNAs and
non-coding RNAs
– Determining the transcriptional structure of genes including their start sites, 5’
and 3’ ends, splicing patterns, and post-transcriptional modifications
– Quantifying the changing expression levels of each transcript during develop-
ment and under different conditions
Transcriptomics makes possible the identification of differentially expressed genes
between different samples, and the significance of those genes can be further examined
by gene enrichment analysis (Huang et al., 2009; Nature Publishing Group, 2014).
4.1 Microarray and RNA-Seq experiments
A microarray analysis is a way to find out the expression levels of even tens of
thousands of genes in a single assay (Quackenbush, 2006). It has made the rapid
and high-throughput quantification of the transcriptome possible. Results from
microarray experiments have provided valuable information about the transcriptome
in different cell types and the changing levels of gene expression under different
conditions (Malone and Oliver, 2011).
A microarray experiment is conducted by arraying seuqnce-specific probes, which
represent thousands of individual genes, on an inert substrate (Quackenbush, 2006).
The design of the probes is usually based on genome sequence or on open reading
frames. RNA is extracted from cells of interest and labelled with one or two colours
of fluorescent dye, or other detectable marker. (Malone and Oliver, 2011) Each RNA
hybridizes with its complementary probe, and the relative fluorescence intensity of
each gene-specific probe is measured to indicate the concentration of the RNA. In
order to be able to do comparisons between assays, the obtained data is normalized
in order to compensate for differences in hybridization, labelling, and detection
efficiencies. After normalization, the data can be filtered in a number of ways, for
instance genes that have minimal variance across the samples can be left out from
further inspection. The collected, normalized, and filtered data is then ready for
analysis like gene enrichment analysis (Quackenbush, 2006).
RNA-Seq is a new method of analysing the transcriptome by a procedure known
as deep sequencing. Transcripts present in the starting material are sampled by
direct sequencing, instead of using the hybridization technique of microarrays. The
sequences are mapped back to a reference genome, and the number of mapped reads
is the measure of the expression level for a gene (Malone and Oliver, 2011).
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Compared to microarrays, RNA-Seq has several advantages. Junctions between
exons can be assayed without prior knowledge of the gene structure, since RNA-Seq
provides direct access to the sequence. Also RNA editing events can be detected.
RNA-Seq can also be used on species for which a full genome sequence is unavailable.
Expressed regions of the genome corresponding to currently unidentified genes can
be easier to detect with sequencing than with microarrays. RNA-Seq makes also
quantifying individual transcript isoforms easier when compared to microarrays
(Malone and Oliver, 2011).
The pros of microarray experiments compared to RNA-Seq are the quality of the
data and cheap price. As microarray experiments have been conducted for a long time,
their biases are understood nowadays. In the early experiments different microarrays
seemed to give different results from the same samples. The fluorescent readout of
the intensities varied between laser scanners. Recognition of biases has led to the
development of quality procedures, for instance experimental and computational
methods have been developed for dealing with variations between laboratories. This
work is still being done with RNA-Seq. Microarray experiments cost also about one
tenth of RNA-Seq experiments. Inadequate coverage of RNA-Seq may be a problem
because of the high amount of expensive reads needed for saturated coverage. This is
not a problem for microarray experiments due to the fixed nature of probes (Malone
and Oliver, 2011).
4.2 Proteomics and transcriptomics
The set of all expressed proteins in a cell, organism, or tissue is called the proteome
(Horgan and Kenny, 2011). It has been assumed, that there is correlation between
mRNA transcripts and protein expression (Haider and Pal, 2013). However, studies
by for instance Gygi et al. (1999) and Ghazalpour et al. (2011) have shown that
there can be low correlation between them. Haider and Pal (2013) have summarized
different factors affecting the relationship between mRNA and protein expression
levels. Factors which influence the efficiency of translation, for instance physical
properties of the transcript, will also influence the correlation between mRNA and
protein. Codon-bias, the way how a number of codons can be used in translating the
same amino acid, also impacts the correlation. Ribosome-density, the number and
distribution of ribosomes in a transcriptional unit, strongly influences the efficiency of
translation. During the cell cycle, high variability of the expression levels of mRNA
results in higher correlation with the protein expression. Eukaryotic mRNA and
proteins have different half-lives, which influences the correlation (Haider and Pal,
2013).
There are different methods for integrating proteomic and transcriptomic data.
A reference data set can be created from a union of proteomic and transcriptomic
data sets. Another way is to extract common functional context of proteomic
and transcriptomic data, for instance by utilizing the Gene Ontology. Topological
networks may be used to find common regulators from proteomic and transcriptomic
data sets. Correlation of transcriptomic and proteomic data can be enhanced also by
merging multiple proteomic and transcriptomic data sets respectively, and conducting
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a correlation analysis between the merged data sets. Missing values of proteomic
data can be predicted by non-linear or linear optimization. Another mathematic
model is multiple regression analysis, which can be used to analyse the contribution
of sequence features in the correlation between mRNA and protein expression, as the
protein abundance depends on other biological factors besides only the abundance of
mRNA. Also clustering and dynamic modelling can be used to compare proteomic
and transcriptomic data (Haider and Pal, 2013).
4.3 Gene Ontology
An ontology is a vocabulary that represents and communicates knowledge about
a topic in addition to a set of relationships between the terms of the vocabulary.
Gene Ontology (GO) project, maintained by Gene Ontology Consortium, aims to
construct a structured, precisely defined, controlled vocabulary that has consistent
descriptions of genes and gene products regardless of species. Since a structured
ontology can be easily dealt with by a computer, one of the main uses of GO is
performing gene enrichment analyses that find out which GO terms are enriched in
a study (Ashburner et al., 2000).
GO terms can be attributes of genes, gene products, or gene-product groups. GO
annotations assign GO terms to gene products. The terms are somewhat hierarchical,
with ‘child’ terms being more specific than their ‘parent’ terms, but unlike in a strict
hierarchy, one term can have multiple parent terms (Ashburner et al., 2000).
GO is divided into three categories: biological process (BP), molecular function
(MF), and cellular component (CC). Biological process involves often a physical or
chemical transformation that is accomplished by molecular functions. It is an objective
to which the gene or its product contributes. For instance ‘immune response’ and
‘regulation of B cell proliferation’ are BP terms. Molecular function is a biochemical
activity of a gene product. For instance ’enzyme binding’ and ‘MHC class II receptor
activity’ are MF terms. Cellular component is the part of the cell where a gene
product is active. For instance ’endoplasmic reticulum’ and ’Golgi apparatus’ are
cellular component terms. A protein can take part in many processes, contain
diverse domains with different molecular functions, and interact with multiple other
proteins or locations in the cell, thus there are plenty of relationships between a gene
product and GO categories. Figure 9 shows a network around BP term ‘immune
response-regulating signalling pathway’ (Ashburner et al., 2000).
26
Figure 9: An example of a biological process ontology which illustrates the complex
relationships between different terms (Ashburner et al., 2000).
4.4 Gene enrichment analysis
Gene enrichment analysis is a way to find out which biological functions are the
most relevant in a given study. The idea is that if a certain process, like immune
response, is significant to a given study, its co-functioning genes should be enriched,
i.e. be more likely to be selected as a relevant group by statistical methods (Huang
et al., 2009). For instance, Cocco et al. (2012) studied different clusters of genes
in the generation of long-lived plasma cells, and found that in a certain cluster a
significant amount of genes were attributed with B cell activation. They were thus
able to conclude that B cell activation was enriched within that cluster of genes.
The enrichment value of a GO term can be quantitatively measured by statistical
methods like Hypergeometric distribution, Chi-square, Binomial probability, and
Fisher’s exact test. It must always be measured against a reference background,
which can be the total genes in a genome, or a narrower set of genes like those
detected by a microarray. Within the same analysis, the reference background should
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be the same, so the results are consistent with each other. There are three ways
to conduct an enrichment analysis, singular enrichment analysis (SEA), gene set
enrichment analysis (GSEA), and modular enrichment analysis (MEA) (Huang et al.,
2009).
A singular enrichment analysis is conducted by first finding out which genes are
differentially expressed between experiment and control samples, and then testing
the enrichment of each annotation term one-by-one in a linear mode. Differentially
expressed genes can be found by t-test, fold change analysis, or their combination.
The enrichment P-value describes the probability of finding a certain amount of
genes associated with the same GO term compared to random chance. Singular
enrichment analysis is able to efficiently extract the major biological meaning behind
large gene lists (Huang et al., 2009).
Student’s t-test is an approach to find out if a gene is differentially expressed
between different conditions. The test is based on the t-statistic assessing the signal-
to-noise ratio of the gene in question and comparing its expression measure for the
two experimental conditions. T-statistic is defined as 1, where Xi is average value
across measurements of the signal-to-noise ratio measured under condition i, and σ2i
is the standard deviation of the mean (Quackenbush, 2006).
t = signal
noise
= difference between groups
variability of groups
= 〈XA〉 − 〈XB〉√
σ2A + σ2B
(1)
There are different ways to use the t-statistic to estimate the probability of a gene
being differentially expressed between the conditions. One approach is to use the
properties of the t-distribution for normally distributed random variables in order
to calculate the probability that for a gene under two conditions (A and B), the
two distributions of the expression measures overlap for a given value of t. This is
based on the assumption that the variabilities of these measurements follow normal
distribution, which is not necessarily always the case for gene expression. However,
the t-test is quite robust to violations of the assumption of normality (Quackenbush,
2006).
Another approach is performing a permutation test that uses the properties of
the expression measures themselves to estimate the significance of a given t-value.
Expression level measurements between the two expression groups are randomly
swapped up to the total amount of possible unique permutations. A value for t is
calculated each time, and it is determined how often an equal or larger t-value occurs
than the one measured for real data. This allows the estimation of the probability that
there is a significant separation between the two expression groups. The probability
can be expressed as P-value, and a cutoff P-value can be defined to be used for
filtering genes for further analysis. For example, if the P-value cutoff is 0.05, then
there is at least 95% chance that a gene can have distinguished expression levels
between groups (Quackenbush, 2006).
One statistical method for conducting singular enrichment analysis is Fisher’s
exact test which utilizes the Hypergeometric distribution works in a following way:
In a gene universe, all genes can be marked either significant or insignificant to a
given study. A null hypothesis is that there is no relationship between a gene being
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significant and being in a given GO category containing K genes. Under the null
hypothesis, the amount of significant genes can be modelled by Hypergeometric
distribution. If there are j significant genes in the given GO category, it is possible
to calculate the probability of getting j or more significant genes in K draws from
the gene universe, without replacement (Falcon and Gentleman, 2008).
Gene set enrichment analysis is similar to singular gene enrichment analysis, but it
takes into account all genes from a microarray experiment. This way all information
from microarray experiment is used, and the factors of the gene selection step do
not impact the outcome of the analysis. It also evaluates the data at the gene set
level, where the sets are formed on the basis of biological knowledge. The goal
of the analysis is to find out whether the members of a gene set show differential
expression between two biological states. This is done by ranking the genes according
to the difference in their expression, and determining where on the list the genes in
a gene set fall into. The calculated enrichment score reflects the degree to which the
gene set is overrepresented in either the top or bottom part of the ranked list. The
significance, or the P-value, of the enrichment score is estimated by a permutation
test (Subramanian et al., 2005).
The third way of doing enrichment analysis is modular enrichment analysis, where
the basic enrichment calculation is similar to singular enrichment analysis. In addition
to singular enrichment analysis, term-to-term relationships are considered by using
genes that have joint GO annotation terms as a reference background. These joint
terms may have unique biological meaning that is not discovered by looking at only
individual GO terms. The downside of the modular enrichment analysis is that terms
or genes which have weak relationships to their neighbours may be excluded from of
the analysis (Huang et al., 2009).
This P-value given by enrichment analysis can be regarded as an advising scoring
system between enriched terms. The P-values themselves can be fragile and influenced
by factors such as the used statistical method, the data source, or the studied biological
phenomenon itself. Therefore, instead of only looking at P-values, also biological
knowledge plays an important role in interpreting the results of enrichment analysis,
in a way that the result should make sense based on a priori biological knowledge.
Also the size of the gene list influences P-values, so that a larger gene list can
have higher statistical power, and subsequently higher sensitivity leading to more
significant P-values. Thus, it is difficult to compare the absolute P-values of different
gene lists (Huang et al., 2009).
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5 Scope of the research
The target of this thesis was to find the enriched GO terms in plasma cells, the
genes comprising those terms and study the effects of those genes on antibody-
secreting S. cerevisiae. The enriched terms and the genes comprising them were
found by computational enrichment analysis. The selected genes were individually
overexpressed and knocked out in antibody-secreting S. cerevisiae.
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6 Materials and methods
6.1 Bioinformatics
The processing and analyzing of data was conducted in R software environment (R
Core Team, 2014). The purpose of the bioinformatics part was to find out which
GO-terms were enriched in plasma cell development, which genes comprised those
terms, and out of those genes, which ones were applicable for testing in S. cerevisiae.
6.1.1 Data selection and pre-processing
Gene expression data from four studies was used in this thesis. All data sets have
been deposited in the Gene Expression Omnibus (GEO) database maintained by the
National Center for Biotechnology Information (NCBI) (Edgar et al., 2002). The
data sets and their respective accession numbers are listed in table 1. All selected
data sets contain data from both naïve B cells and matured plasma cells, and these
states are compared in the enrichment analysis.
Table 1: Data sets used in this study.
Data set Contributors GEO accession number
Expression profiles from a variety of
resting and activated human immune cells Abbas et al. (2005) GSE22886
In vitro generation of long-lived
human Plasma Cells Cocco et al. (2012) GSE41208
Analysis of proposed human B1 cells Covens et al. (2013) GSE42724
Gene expression by human splenic
B-cell subsets Good et al. (2009) GSE13411
Data sets were downloaded to R using the GEOquery package (Davis and Meltzer,
2007) and quantile normalized with the affyPLM package (Bolstad, 2004), except
the already normalized data of Cocco et al. (2012). Probes without EntrezID were
removed. Data sets from Good et al. (2009) and Abbas et al. (2005) were log2-
transformed, and the other two sets had already been transformed. Nine data subsets
were formed from the original data sets based either on the age of the plasma cells, or
whether they were harvested from peripheral blood, human spleen, or bone marrow.
The subsets and their abbreviations are described in table 2.
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Table 2: Data subsets and their abbreviations used in this thesis.
Data subset Abbreviation
Abbas et al. (2005) subset peripheral blood A A1
Abbas et al. (2005) subset bone marrow A A2
Abbas et al. (2005) subset peripheral blood B A3
Abbas et al. (2005). subset bone marrow B A4
Cocco et al. (2012), subset peripheral blood, day 20 CC1
Cocco et al. (2012), subset peripheral blood subset day 41 CC2
Cocco et al. (2012), subset bone marrow CC3
Covens et al. (2013). subset peripheral blood C1
Good et al. (2009), subset human spleen GT1
Annotations for the Illumina HumanHT-12 V4.0 expression beadchip, Affymetrix
Human Gene 1.0 ST Array [transcript (gene) version], Affymetrix Human Genome
U133A Array and Affymetrix Human Genome U133B Array platforms were pro-
vided by the illuminaHumanv4.db (Dunning et al.), hugene10sttranscriptcluster.db
(MacDonald), hgu133a2.db (Carlson, a), and hgu133b.db (Carlson, b) packages
respectively. The annotation packages and their respective data subsets are described
in table 3.
Table 3: Annotation packages corresponding to data subsets.
Data subset Annotation package
A1 hgu133a2.db
A2 hgu133a2.db
A3 hgu133b.db
A4 hgu133b.db
CC1 illuminaHumanv4.db
CC2 illuminaHumanv4.db
CC3 illuminaHumanv4.db
C1 hugene10sttranscriptcluster.db
GT1 hgu133a2.db
6.1.2 GO-term enrichment analysis
Differentially expressed genes were determined from the rows of the data subsets by
rowttests function from genefilter package (Gentleman et al.). The cutoff P-values
were different when performing enrichment analysis for biological process (BP) or
molecular function (MF) GO-terms. They are listed in tables 4 and 5, for BP and
MF analyses respectively. The P-values were determined in order to yield lists
of terms which were able to be processed manually, therefore lists with possibly
hundreds of terms were trimmed down by decreasing the P-value. Fold changes
were analysed using analyzeelbow function from ELBOW package (Zhang et al.,
2014), which contains a method for determining biologically significant fold changes.
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Only expression values with significant fold change were considered in the GO-term
enrichment analysis.
Table 4: P-value cutoffs for t-tests filtering the data for BP analysis.
Data subset Cutoff for BP analysis
A1 1−4
A2 1−5
A3 1−3
A4 1−4
CC1 3−4
CC2 5−5
CC3 5−5
C1 1−4
GT1 5−3
Table 5: P-value cutoffs for t-tests filtering the data for MF analysis.
Data subset Cutoff for MF analysis
A1 5−4
A2 1−4
A3 5−4
A4 1−4
CC1 1−3
CC2 1−4
CC3 1−3
C1 1−4
GT1 5−3
GO-term enrichment analysis was done with the GOstats package, utilizing the
hypergeometric test (Falcon and Gentleman, 2007). As the sizes of the data sets
varied, unique P-values were determined for each data subset. The ones chosen
were set between 0.01 and 1−6 to reduce the chances of getting false negative or
positive results. P-values for biological process (BP) and molecular function (MF)
enrichment analysis are listed in tables 6 and 7. The results of gene enrichment
analyses from different data subsets were compared with each other using termLists
function (Appendix C), which counts the subsets where each GO-term was enriched.
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Table 6: P-values for conducting enrichment analyses for BP terms and how many
terms were found to be enriched.
Data subset P-value for BP terms
A1 1−5
A2 1−6
A3 5−4
A4 1−3
CC1 1−5
CC2 2−5
CC3 1−6
C1 1−3
GT1 1−4
Table 7: P-values for conducting enrichment analyses for MF terms and how many
terms were found to be enriched.
Data subset P-value for MF terms
A1 5−3
A2 5−3
A3 1−2
A4 1−2
CC1 1−3
CC2 5−3
CC3 1−4
C1 5−3
GT1 1−2
6.1.3 The most differentially expressed genes and genes comprising se-
lected GO-terms
The most differentially expressed genes in each data set were determined by using
rowttests function from the genefilter package (Gentleman et al.), and setting the
P-value cutoffs according to table 8. The probe lists were converted to gene names
by using the respective annotation packages listed in table 3.
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Table 8: P-values for finding the most differentially expressed genes, and the sizes of
the resulting lists of genes.
Data subset P-value
A1 1−8
A2 1−8
A3 1−7
A4 1−7
CC1 1−5
CC2 1−6
CC3 1−6
C1 1−6
GT1 1−4
Seven GO-terms listed in table 9 were selected for closer inspection. From
those, the genes comprising each term were extracted by extractGenes function
(Appendix D). The formed lists of genes were compared with the lists of the
most differentially expressed genes to find out possible overlaps. This was done by
compareGeneLists function (Appendix F). The fold change of each gene in different
data subsets was found by findFoldChange function (Appendix G). Whether the
gene had a homologue in S. cerevisiae was determined by manually searching Uniprot
(Consortium, 2014).
Table 9: Selected GO-terms and their GO-IDs.
GO-term MF or BP GO-ID
NADH dehydrogenase activity MF GO:0003954
Oxidoreductase activity MF GO:0016491
Response to endoplasmic reticulum stress BP GO:0034976
Cellular response to unfolded protein BP GO:0034620
Protein targeting to ER BP GO:0045047
ER-associated ubiquitin-dependent protein catabolic process BP GO:0030433
Cell activation BP GO:0001775
6.2 Laboratory experiments
Four genes were chosen for knockout and overexpression experiments in antibody-
secreting S. cerevisiae. The used strain was W303α strain ( ATCC®208353TM,
genotype: MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15) having a DNA
fragment expressing IgG integrated into HIS3-site by the use of pRS303N vector
described in Taxis and Knop (2006). The IgG expression cassette has genes for
the light and heavy chain encoding the monoclonal antibody C2B8 under GAL1-
promoter. The chosen genes were Sec61 beta subunit (SBH1), glycerol-3-phosphate
dehydrogenase 2 (mitochondrial) (GPD2), thioredoxin 1 (TRX1), and thioredoxin 2
(TRX2). Each gene was both knocked out and overexpressed in the yeast, and the
effects were analyzed by enzyme-linked immunosorbent assay (ELISA).
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6.2.1 Primers for the PCR steps
LoxP-kanMX-loxP marker cassettes (Güldener et al., 1996) were used for knockout
experiments. 50 bp from both sides of each gene were combined with 20 bp from up-
or downstream loxP site. The primers are described in table 10.
Table 10: Knockout primers. The bolded parts are loxP sites and the rest of the
sequences are from either side of the genes.
Primer Sequence Tm (°C)
SBH1, forward 5’-ATG TCA AGC CCA ACT CCT CCA GGT GGT CAA CGT ACT TTG CAA AAG AGA AAGTA CGC TGC AGG TCG ACA AC-3’ 91.0
SBH1, reverse 5’-TTA AAA TAA CTT ACC GGC AAC TTT AGA AAT AAC ATG TAA TGC AAC AAC AGCCA CTA GTG GAT CTG ATA TC-3’ 81.4
GPD2, forward 5’-ATG CTT GCT GTC AGA AGA TTA ACA AGA TAC ACA TTC CTT AAG CGA ACG CAGTA CGC TGC AGG TCG ACA AC-3’ 88.7
GPD2, reverse 5’-CTA TTC GTC ATC GAT GTC TAG CTC TTC AAT CAT CTC CGG TAG GTC TTC CACCA CTA GTG GAT CTG ATA TC-3’ 86.1
TRX1, forward 5’-ATG GTT ACT CAA TTC AAA ACT GCC AGC GAA TTC GAC TCT GCA ATT GCT CAGTA CGC TGC AGG TCG ACA AC-3’ 90.9
TRX1, reverse 5’-TTA AGC ATT AGC AGC AAT GGC TTG CTT AAT AGC CGC TGG GTT GGC ACC AACCA CTA GTG GAT CTG ATA TC-3’ 89.1
TRX2, forward 5’-ATG GTC ACT CAA TTA AAA TCC GCT TCT GAA TAC GAC AGT GCT TTA GCA TCGTA CGC TGC AGG TCG ACA AC-3’ 89.0
TRX2, reverse 5’-CTA TAC GTT GGA AGC AAT AGC TTG CTT GAT AGC AGC TGG GTT GGC ACC GACCA CTA GTG GAT CTG ATA TC-3’ 88.4
Overexpression primers were designed according to exonuclease and ligation-
independent cloning (ELIC) protocol (Koskela and Frey, 2014). For genes SBH1 and
GPD2, the forward primer was designed to start at the gene promoter, and for both
thioredoxins the forward primer started at the beginning of the gene. The vector
used in overexpression experiments was pRS415-Tef, described in Mumberg et al.
(1995). The primers are described in table 11.
Table 11: Overexpression primers. The 5’ end of each primer is complementary to the
plasmid and the 3’ end is complementary to the gene or the promoter. Restriction
enzymes are in the middle. The first Tm value is the Tm of the whole primer, and
the second one is Tm of the part complementary to the gene or the promoter.
Primer Sequence Tm1 (°C) Tm2 (°C)
5’-pAF5-SacI-SBH1-3’ 5’ -GGG AAC AAA AGC TG-GAG CTC-GTT CAT TAA ATT TCT A-3’ 75.2 39.1
5’-pAF5-XhoI-SBH1-3’ 5’-AAC TAA TTA CAT GA-CTC GAG-TTA AAA TAA CTTA CCG-3’ 66.9 43.1
5’-pAF5-SacI-GPD2-3’ 5’ -GGG AAC AAA AGC TG-GAG CTC-CTA TTA TAG TGG GGA GAG-3’ 77.6 48.9
5’-pAF5-XhoI-GPD2-3’ 5’-AAC TAA TTA CAT GA-CTC GAG-CTA TTC GTC ATC GAT GTC-3’ 74.2 54.2
5’-pAF5-SpeI-TRX1-3’ 5’-CTA AGT TTT CTA GA-ACT AGT-ATG GTT ACT CAA TTC-3’ 63.0 41.4
5’-pAF5-XhoI-TRX1-3’ 5’-AAC TAA TTA CAT GA-CTC GAG-TTA AGC ATT AGC AGC-3’ 70.1 47.6
5’-pAF5-SpeI-TRX2-3’ 5’-CTA AGT TTT CTA G-ACT AGT-ATG GTC ACT CAA TTA-3’ 64.0 42.7
5’-pAF5-XhoI-TRX2-3’ 5’-AAC TAA TTA CAT GA-CTC GAG-CTA TAC GTT GGA AGC-3’ 71.3 46.3
All primers were synthesized by Eurofins MWG Operon (Germany).
6.2.2 PCR and the preparation of DNA fragments
When preparing DNA fragments for knockout experiments, plasmid pUG6 carrying
the loxP–kanMX–loxP disruption module (Güldener et al., 1996) was used as a
template. In each of the four reaction mixes there were 3 mM plasmid, 2 mM
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of both forward and reverse primers, 0.4 mM dNTPs, and 10 mM Phusion High-
Fidelity DNA Polymerase (Thermo Fisher Scientific) in Phusion HF Buffer (Thermo
Fisher Scientific). The PCR programme is shown in table 12. After the final 10
minutes extension step, the PCR products were stored at 4 °C. After PCR, loading
dye (Thermo Fisher Scientific) was added, and products were run on 0.7% agarose
gel. Purification from gel was done with NucleoSpin Gel and PCR Clean-up kit
(Macherey-Nagel) according to the manufacturer’s protocol, except the final elution
which was done to 20 µl H2O.
Table 12: PCR programme for preparing DNA fragments for knockouts. Lid temper-
ature was 105 °C, and preheating was on.
Step Temperature (°C) Time Cycles
1 98 30 s
2 98 10 s
3 54 30 s
4 72 45 s 6 x to step 2
5 98 10 s
6 68 30 s
7 72 45 s 36 x to step 5
8 72 10 min
For preparing DNA fragments for overexpression experiments, 0.04 mM yeast
genomic DNA was used as template DNA. Otherwise the mixtures were same as in
the knockouts described above. PCR programmes were different for GPD2 and the
other three genes, since the Tm values of the primers were different. For GPD2, the
programme was the same as in table 12, except the temperature was 52 °C in step 3,
and 77 °C in step 6. For the others, the programme was also the same as in table 12,
except the temperature was 46 °C in step 3 and 67 °C in step 6, and steps 4 and 7
both lasted for 15 s.
After PCR, loading dye (6x DNA Loading Dye, Thermo Fisher Scientific) was
added, and GPD2 was run on 0.7% agarose gel, and the others were run on 1.2%
agarose gel. Purification was done with NucleoSpin Gel and PCR Clean-up kit
(Macherey-Nagel) according to the manufacturer’s protocol. The centrifuge used in
all purifications was Eppendorf Centrifuge 5418. DNA concentrations were measured
on Take3-platform with Eon Microplate Spectrophotometer (BioTek).
6.2.3 Plasmid generation and selection
Plasmid generation was done according to ELIC protocol (Koskela and Frey, 2014).
Vector was digested in a mixture of 30 µl in 1 x FastDigest Green Buffer (Thermo
Fisher Scientific), containing 5 µl pRS415-Tef vector, 1 FDU XhoI restriction enzyme
(FastDigest, Thermo Fisher Scientific), and 1 FDU either SpeI (FastDigest, Thermo
Fisher Scientific) or Ecl136II (FastDigest, Thermo Fisher Scientific) restriction enzyme.
Mixtures were incubated overnight at +37 °C, and run on 0.7% agarose. Purification
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was done with NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) according
to the manufacturer’s protocol.
The amount of insert was calculated according to equation
vector(ng) ∗ insert(kb)
vector(kb) ∗ 3 = insert(ng) (2)
Vector amount was 80 ng for GPD2 insert, and 100 ng for all others. SBH1 and
GPD2 inserts were mixed with the plasmid digested with Ecl136II restriction enzyme,
and the other two were mixed with the plasmid digested with SpeI restriction enzyme.
H2O was added for total volume of 10 µl. Transformation into chemical competent
cells and screening of colonies were done as described in ELIC protocol (Koskela
and Frey, 2014). Enzymes chosen for screening colonies for correct insert were
Ecl136II and XhoI for SBH1, Eco31I for GPD2, EcoRI for TRX1, and SpeI and
XhoI (all enzymes were FastDigest enzymes by Thermo Fisher Scientific) for TRX2,
respectively. Test digestion mixtures were analyzed on 1% agarose.
6.2.4 Transformation
Both knockout cassettes and overexpression plasmids were transformed into YEK018
yeast by LiAc transformation from liquid culture. The yeast strain is described in
the beginning of this section about laboratory experiments. Also pEK7 plasmids
were transformed into knockout yeast strains after the confirmation of the knockout,
so they could be cultivated in the same conditions as the overexpression yeast strains.
This plasmid is like pRS415 plasmid (Mumberg et al., 1995), but lacks polylinker,
promoter, and terminator removed with SacI/NaeI sites, thus it has only the empty
vector backbone with LEU2 marker. Cells were grown overnight in 3 ml YPD, 30
°C, 220 RPM. OD600 values were measured with eppendorf BioPhotometer Plus
machine, and samples were diluted to 0.5 OD600 (knockout cassettes) or 0.4 OD600
(overexpressions), and incubated at 30 °C, 220 RPM for three hours. Cells were
harvested by centrifugation at 3900 RPM for 5 minutes. After resuspending the
pellets in 50 ml sterile water the centrifugation was repeated. The pellets were
resuspended in 500 µl solution containing 1 x TE and 0.1% LiAc, centrifuged for 3
minutes at 3600 RPM, and resuspended again in the same solution, the amount of
which was 1/50 of the original culture volume.
100 µl of the harvested cells were mixed with either 500 ng of knockout cassettes
or 600 ng of insertion plasmids. 30 ng denaturated salmon sperm was added as
the carrier DNA along with 1 ml solution containing 1x TE, 0.1% LiAc, and 40%
PEG, and the mixtures were incubated for 1 hour at 30 °C. After incubation, 120
µl DMSO was added, and cells were heat shocked at 42 °C for 10 minutes, cooled
immediately in ice for 3 minutes, and centrifuged for 5 minutes at 3000 RPM. In
overexpression experiments and when adding pEK7 plasmid to knockout strains,
the pellets were resuspended in 100 µl sterile water, and plated on SD-Leu plates.
When doing knockouts, the pellets were resuspended in 1 ml YPD and incubated for
three hours at 30 °C, 220 RPM. The centrifugation was repeated and pellets were
resuspended in 100 µl sterile water, and plated on YPD plates supplemented with
38
200 µg/ml G418. Further yeast cultivation is described in section 6.2.6. Centrifuge
used for harvesting cells was Eppendorf Centrifuge 5810R, and the centrifuge used
in other steps was Eppendorf Centrifuge 5418.
6.2.5 Verification of knockouts
After transformations, knockout yeasts were plated on YPD plates supplemented
with 200 µg/ml G418, which is selective for kanMX marker in the knockout cassettes,
and incubated at 30 °C for four days. In addition to the cultivation on selective
media, the knockouts were colony-purified by selecting four colonies of each knockout
yeast and plating them on new YPD plates supplemented with 200 µg/ml G418.
These were incubated for two days at 30 °C. After storing the plates at 4 °C for 12
days, a colony from each sample on the new plates was transferred on a new YPD
plates supplemented with 200 µg/ml G418 and incubated at 30 °C for three days.
After incubation, one colony from each knockout yeas strain was chosen to be grown
overnight at YPD (30 °C, 210 RPM) and stored at -80 °C.
6.2.6 Yeast cultivation and IgG expression
Overexpression yeast strains and knockout yeast strains containing the plasmid pEK7
were plated on SD-Leu plates, and incubated at 30 °C for two days. Two colonies
from each sample were transferred to new SD-Leu plates that were incubated in
30 °C for four days. One colony from each yeast was selected and suspended into 1
x SD-Leu media containing 2% raffinose and 10 mM NaPO4 as buffer. Cells were
grown for 41 hours at 30 °C, 220 RPM. Normally they would have been incubated
only for overnight, but there was not enough growth. These samples were used for
ELISA.
OD600 values were measured with eppendorf BioPhotometer Plus machine, and
samples were diluted to 0.5 OD600. Dilution mixture was the same as the SD-Leu
media described above, supplemented with 0.05 mg/ml BSA (bovine serum albumin).
Cells were grown on deep-well plate at 30 °C, 220 RPM for 5 hours 40 minutes.
Protein expression was induced with different galactose concentrations (0.5%, 1%,
2%, and 4%), and samples were incubated for 24 h at 25 °C, 230 RPM. The cells
were centrifuged at 3900 RPM for 10 minutes, OD600 values were measured with
Eon Microplate Spectrophotometer (BioTek), and 285 µl supernatant from each
sample was mixed with 15 µl 20 x PBT (PBS (135 mM NaCl, 2.5 mM KCl, 10 mM
Na2HPO4, 1.75 mM KH2PO4) and 0.5% Tween-20), and stored in -22 °C.
6.2.7 ELISA
A 96-well plate was coated the day before by adding 38.5 µl per well of 4.2 µl of
goat anti Human IgG (Fc specific) antibody (Sigma-Aldrich, Helsinki, Finland) in 20
ml 1 x PBS, and incubating the plate overnight at 7 °C with shaking. ELISA was
conducted according to the following protocol:
Each well on the plate was washed 5 times with 200 µl PBT, and incubated
with 200 µl PBT in room temperature, with shaking, for 45 minutes. The washing
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was repeated, and samples along with standard series were added to each well. The
volume of each sample and standard series specimen was 200 µl. The standard
series consisted of human IgG standard antibody, obtained from Calbiochem (Merck
Millipore, Billerica, USA), in PBT with the concentrations of 0, 0.5, 0.25, 0.125,
0.0625, 0.03125, 0.015625, and 0.0078125 mg/ml. The plate was incubated at +22
°C with shaking for 90 minutes, and washed 5 times with 200 µl PBT per well.
100 µl per wellof 1:4,000 dilution of goat anti-Human IgG (Fc specific)-peroxidase
labelled antibody (Sigma-Aldrich, Helsinki, Finland) was added as detection antibody
in PBT, with the total volume of 200 µl per well. The plate was incubated for 1 hour
in room temperature, with shaking, and washed 5 times with 200 µl PBT per well.
80 µl of substrate consisting of 0.2 mg/ml o-phenylenediamine per well in 0.009 %
H2O2 and 0.05 M phosphate-citrate buffer, was added to each well and incubated for
8 minutes. Reaction was stopped with 100 µl per well of 3 M H2SO4. The signal was
measured by Synergy 2 plate reader (BioTek) and the data analysed with Gen5 2.01
software (BioTek). ELISA was conducted on Hamilton Microlab Star workstation
(Hamilton Company), operated with the manufacturer’s software. ELx405 Select
Deep Well Washer (BioTek) was connected on the machine along with the above
plate reader.
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7 Results and discussion
7.1 Enriched GO-terms and genes associated with them
The enrichment analysis was evaluated for the overrepresentation of gene ontology
(GO) terms, and conditional hypergeometric calculation was used. Analysis was
conducted separately for each of the nine data subsets listed in table 2 and for both
biological process (BP) and molecular function (MF) ontologies, thus 18 analyses
were conducted in total. The background gene universe comprised of all the genes
present in the respective microchip used in the original microarray experiment. The
analyses resulted in total of 75 BP GO-terms and 67 MF GO-terms.
P-value cutoff parameters for filtering the data and conducting enrichment analyses
can be found in tables 13, 14, 15, and 16 respectively. The chosen P-values were
aimed to minimize both the false positive and false negative values. When filtering
data, cutoff P-values ranged from 5−3 to 1−5. The aim was to have a sufficient list
of probes for the fold change analysis and for the further enrichment analysis while
keeping the resulting lists short enough that the results of the enrichment analysis
could be processed manually. The lower values were used for data subsets which
had plenty of probes with significant change between the initial and final conditions.
The aim was to filter the list and find the most significant ones from a larger gene
list. The P-values for the enrichment analyses ranged from 1−2 to 1−6. The values
were chosen in order to gain lists of terms which were not too long to be processed
manually. These values yielded lists of enriched terms ranging from 5 to 26 terms.
Table 13: P-value cutoffs for t-tests filtering the data for BP analysis.
Data subset Cutoff for BP analysis Genes out of total
A1 1−4 1159/19915
A2 1−5 721/19915
A3 1−3 1057/15094
A4 1−4 502/15094
CC1 3−4 558/34298
CC2 5−5 458/34298
CC3 5−5 493/34298
C1 1−4 505/19962
GT1 5−3 340/19915
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Table 14: P-value cutoffs for t-tests filtering the data for MF analysis.
Data subset Cutoff for MF analysis Genes out of total
A1 5−4 1926/19915
A2 1−4 1394/19915
A3 5−4 803/15094
A4 1−4 502/15094
CC1 1−3 1208/34298
CC2 1−4 682/34298
CC3 1−3 2133/34298
C1 1−4 505/19962
GT1 5−3 340/19915
Table 15: P-values for conducting enrichment analyses for BP terms and how many
terms were found to be enriched.
Data subset P-value for BP terms Amount of terms
A1 1−5 19
A2 1−6 20
A3 5−4 5
A4 1−3 26
CC1 1−5 10
CC2 2−5 11
CC3 1−6 13
C1 1−3 8
GT1 1−4 8
Table 16: P-values for conducting enrichment analyses for MF terms and how many
terms were found to be enriched.
Data subset P-value for MF terms Amount of terms
A1 5−3 17
A2 5−3 17
A3 1−2 5
A4 1−2 11
CC1 1−3 5
CC2 5−3 12
CC3 1−4 8
C1 5−3 7
GT1 1−2 5
Complete lists of the enriched terms in all data subsets are listed in appendix H,
and the terms enriched in more than one data subset are listed in tables 17 and 18.
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The enriched GO-terms showed a lot of variation between data subsets. 21 out of 75
BP terms and 11 out of 67 MF terms were enriched in more than one data subset.
These BP terms were all associated with cell activation or B cell development into
plasma cells. The MF terms enriched in multiple data subsets comprised of broad
terms, such as enzyme binding, and terms associated with B cell development, like
MHC class II receptor activity. Of the data subsets, A2 had most BP (15 terms) and
MF (9 terms) terms common with at least one other subset. CC3 did not have any
BP terms common with the other subsets, and A3 had no MF terms common with
the others. The origin of the cells does not seem to affect how many of the terms
were common with the other subsets, as both subsets A2 and CC3 comprised cells
harvested from bone marrow.
Terms enriched in the data of (Cocco et al., 2012) can be found in their supple-
mental data. 18/21 of the BP terms enriched in multiple data subsets were also
enriched in the study by Cocco et al. (2012). The missing terms were lymphocyte
proliferation, regulation of B cell proliferation, and regulation of response to stimulus.
The first two ones were not enriched in any of the data subsets formed from the data
of Cocco et al. (2012), and the third one had its child terms, negative regulation of
response to stimulus and positive regulation of response to stimulus, found to be
enriched. 5/11 of the MF terms enriched in multiple data sets were found to be
enriched in the study by Cocco et al. (2012). Of the terms not found to be enriched
by Cocco et al. (2012), poly(A) RNA binding and phosphatidylinositol 3-kinase
binding were found in data subsets from Cocco et al. (2012). This is most likely due
to different algorithms used in the enrichment analysis. The other four MF terms
not found to be enriched in the data of Cocco et al. (2012) were histone binding,
nucleic acid binding, chromatin binding, and CD8 receptor binding.
Romijn et al. (2005) studied the expression levels of developing plasma cells.
They were able to quantify the expression level 234 proteins at every one of the total
of five inspected time points during plasma cell development.They did not utilize GO
annotation, but did annotate the proteins according to their function into 11 distinct
categories, plus 12th one for all other functions. The categories were immune system,
ER targeting and folding, thiol redox balance, cytosolic and mitochondrial chaperones,
translation, degradation, signaling, membrane transport, metabolism, cytoskeleton,
and cell cycle. Almost all of the BP terms enriched in multiple data subsets can
be grouped into the immune system category, except the broad terms regulation
of response to stimulus, cell activation, positive regulation of cell activation, and
regulation of cell activation, which did not fit into any of the categories formed. B cell
receptor signaling pathway is also involved in signaling. Five of the MF terms enriched
in multiple data subsets were involved with cell cycle (histone binding, nucleic acid
binding, chromatin binding, poly(A) RNA binding, phosphatidylinositol 3-kinase
binding), three with immune system (MHC class II receptor activity, CD8 receptor
binding, antigen binding), one with translation (structural constituent of ribosome),
one with signaling (MHC class II receptor activity), and two were uncategorized
(enzyme binding and protein kinase binding). Except the very broad terms, all of the
terms enriched in multiple data subsets can be assigned into the categories Romijn
et al. (2005) found enriched, which supports that these terms are indeed enriched in
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plasma cells.
van Anken et al. (2003) studied the protein expression during plasma cell de-
velopment. They divided the enriched proteins into seven functional categories,
cytoskeleton, cytosolic chaperones, mitochondrial chaperones, metabolism, redox
balance, ER resident proteins, and immune response. As stated above, most of the
BP terms and three of the MF terms enriched in multiple data subsets were involved
with immune response. The other terms enriched in multiple data subsets do not
clearly fall into any of the categories formed by van Anken et al. (2003), which in
part shows how data from proteomic study like the one by van Anken et al. (2003)
does not necessarily correlate with data from transcriptomics studies, as stated in
section 4.2.
Table 17: Enriched BP terms that appear in more than one data subset, and their
respective data subsets.
Biological process term Amount Subsets
immune response 6 CC1, CC2, C1, GT1, A1, A2
immune response-activating cell surface receptor signaling pathway 6 CC1, CC2, GT1, A1, A2, A4
B cell activation 5 CC1, CC2, A1, A2, A4
activation of immune response 4 CC1, A1, A2, A4
immune response-regulating signaling pathway 4 CC1, A1, A2, A4
positive regulation of immune system process 4 CC1, C1, A2, A4
B cell receptor signaling pathway 3 CC1, A1, A2
positive regulation of lymphocyte activation 3 CC1, GT1, A2
regulation of response to stimulus 3 CC1, CC2, A1
regulation of leukocyte activation 3 CC2, GT1, A2
regulation of B cell proliferation 3 C1, A1, A2
T cell activation 3 GT1, A2, A4
leukocyte activation 2 CC1, A4
cell activation 2 CC2, A3
lymphocyte activation 2 CC2, A3
positive regulation of cell activation 2 GT1, A2
regulation of lymphocyte activation 2 A1, A4
regulation of cell activation 2 A1, A4
lymphocyte proliferation 2 A1, A2
immune effector process 2 A1, A2
lymphocyte differentiation 2 A2, A4
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Table 18: Enriched MF terms that appear in more than one data subset, and their
respective data subsets.
Molecular function term Amount Subsets
enzyme binding 4 CC1, CC2, C1, A2
antigen binding 4 CC2, GT1, A1, A4
poly(A) RNA binding 3 CC1, A1, A2
protein kinase binding 3 CC1, CC2, A2
phosphatidylinositol 3-kinase binding 3 CC2, A1, A2
MHC class II receptor activity 3 CC3, GT1, A1
histone binding 3 A1, A2, A4
structural constituent of ribosome 2 CC1, A2
nucleic acid binding 2 A1, A2
chromatin binding 2 A1, A2
CD8 receptor binding 2 A1, A2
Seven terms out of the 142 enriched BP and MF terms were chosen for closer
inspection on the basis of prior biological knowledge and the cell biology of the
yeast. The chosen terms were NADH dehydrogenase activity, oxidoreductase activity,
response to endoplasmic reticulum stress, cellular response to unfolded protein, protein
targeting to ER, ER-associated ubiquitin-dependent protein catabolic process, and
cell activation. NADH dehydrogenase activity and oxidoreductase activity are MF
terms, the others are BP terms. Out of these seven terms only ER-associated
ubiquitin-dependent protein catabolic process was not enriched in the study by Cocco
et al. (2012).
As stated in sections 2 and 3, the ability to secrete proteins efficiently is vital
for both yeasts used as cell factories and plasma cells. The GO-terms ‘response to
endoplasmic reticulum stress’, ‘ER-associated ubiquitin-dependent protein catabolic
process’, ‘cellular response to unfolded protein’, and ‘protein targeting to ER’ are
all associated with the secretory pathway. ‘Oxidoreductase activity’ and its child
term (Ashburner et al., 2000) ‘NADH dehydrogenase activity’ were found interesting,
since during the production of antibodies the increased disulphide bond formation
induces pressure on the redox conditions of the cell (Masciarelli and Sitia, 2008).
‘Cell activation’ was chosen because it was thought to comprise genes related to
active cell metabolism in general.
126 genes in total were found to be associated with the chosen GO-terms. In
order to see which of them contributed the most to plasma cell development, they
were compared with the lists of the most differentially expressed genes in all separate
data subsets. The P-value cutoffs for selecting the most differentially expressed
genes are listed in table 8. The amount of genes yielded by the P-values ranged
from 10 to 72 for different data subsets, which was deemed suitable for minimizing
both false negative and false positive results. The P-values and the sizes of the
gene lists yielded are listed in table 19. The most differentially expressed genes
of each data subset are listed in appendix I. The most overlap was found among
the genes associated with cell activation: 22 out of 53 genes were also identified as
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the most differentially expressed ones. The smallest overlap was among the genes
associated with NADH dehydrogenase activity, of which none were identified as the
most differentially expressed genes.
Table 19: P-values for finding the most differentially expressed genes, and the sizes
of the resulting lists of genes.
Data subset P-value Size of the list
A1 1−8 32
A2 1−8 72
A3 1−7 29
A4 1−7 46
CC1 1−5 17
CC2 1−6 39
CC3 1−6 19
C1 1−6 55
GT1 1−4 10
Out of the 126 genes associated with the chosen GO-terms, 24 had a S. cerevisiae
homologue, and were therefore considered for the laboratory experiments. These 24
genes are listed in table 20 along with their mean fold changes and standard deviations
(if applicable) across the data subsets. Nearly all of the genes were upregulated.
Half of the genes were associated with oxidoreductase activity, nine were ribosomal
proteins associated with protein targeting to ER, two were associated with both
cellular response to unfolded protein and response to endoplasmic reticulum stress,
and one was associated with ER-associated ubiquitin-dependent protein catabolic
process.
The genes selected for in vivo testing were Sec61 beta subunit (SBH1), glycerol-3-
phosphate dehydrogenase 2 (mitochondrial) (GPD2) and thioredoxin (TRX). SBH1
was chosen since it is involved in the uptake of the nascent polypeptide chain into the
lumen of the ER (Toikkanen et al., 1996), and therefore its overexpression could lead
into improved rate of polypeptide chain uptake into the ER, resulting in increased
rate of antibody secretion.
Since there are two cytoplasmic thioredoxins, thioredoxin 1 (TRX1) and thiore-
doxin2 (TRX2), in S. cerevisiae, they were both used in the in vivo testing. Thiore-
doxins act as hydrogen donors in redox reactions, and besides regulating the redox
balance in the cytoplasm, they are involved in multiple cellular processes, including
protein folding. Antibodies are rich in disulphide bonds, which increase their stability,
therefore the ER needs to have a large oxidative capacity to meet the need of rapid
introduction of disulphide bonds into antibodies. Disulphide bond formation is based
on redox reactions, where two cysteines are oxidized by removing two electrons
forming a covalent bond. During antibody production and expansion of the ER, an
excess of electrons is produced due to the disulphide bond formation. This induces
pressure on the redox conditions of the cell, and so additional buffer capacity can
be needed the cytosol and mitochondria to maintain the redox homeostasis in these
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compartments (Masciarelli and Sitia, 2008; Romijn et al., 2005; Trotter and Grant,
2002). GPD2 oxidizes NADH, and is thus also involved in the redox homeostasis
maintenance (Vemuri et al., 2007). It was also deemed interesting since it was the
only downregulated gene which did not encode ribosomal protein subunit and which
homologue in S. cerevisiae was not putative. It catalyses the production of glycerol
under anaerobic growth conditions, and controls the rate of glycerol formation in S.
cerevisiae (Cronwright et al., 2002; Hubmann et al., 2011).
According to the findings of van Anken et al. (2003), proteins functioning in
redox balance, like the thioredoxins and glycerol-3-phosphate dehydrogenase, and
ER resident proteins, such as Sec61 beta subunit, are enriched in the development of
plasma cells, which supports their choice for the experiments in vivo.
Table 20: Original genes of the selected GO-terms which have a S. cerevisiae
homologue. Two of the genes are associated with two different GO-terms. Mean is
the mean of the fold changes in all data subsets, and SD is the standard deviation.
The genes which have no value for standard deviation were present in only one data
subset.
GO term Gene Mean SD
Cellular response to unfolded protein /
Response to endoplasmic reticulum stress X-box binding protein 1 4.73 0.76
Cellular response to unfolded protein /
Response to endoplasmic reticulum stress alanyl-tRNA synthetase 2.65 0.51
ER-associated ubiquitin-dependent protein
catabolic process Sec61 beta subunit 2.68 0.50
Protein targeting to ER ribosomal protein L12 -0.28
Protein targeting to ER ribosomal protein L15 -0.78 0.71
Protein targeting to ER ribosomal protein L22 -0.56 0.16
Protein targeting to ER ribosomal protein L27 -0.31
Protein targeting to ER ribosomal protein L38 -0.28
Protein targeting to ER ribosomal protein S2 -0.21
Protein targeting to ER ribosomal protein S23 -0.20
Protein targeting to ER ribosomal protein S27 -0.28 0.04
Protein targeting to ER ribosomal protein S29 -0.22
Oxidoreductase activity saccharopine dehydrogenase (putative) -0.15
Oxidoreductase activity
pterin-4 alpha-carbinolamine
dehydratase/dimerization cofactor of
hepatocyte nuclear factor 1 alpha
1.38
Oxidoreductase activity glutaredoxin 2 0.99
Oxidoreductase activity thioredoxin 2.13 0.30
Oxidoreductase activity isocitrate dehydrogenase 2(NADP+), mitochondrial 2.56 0.43
Oxidoreductase activity ubiquinol-cytochrome c reductase,complex III subunit VII, 9.5kDa 2.03
Oxidoreductase activity glycerol-3-phosphate dehydrogenase 2(mitochondrial) -0.15
Oxidoreductase activity protoporphyrinogen oxidase 0.74
Oxidoreductase activity methylsterol monooxygenase 1 1.64
Oxidoreductase activity cytochrome c oxidase subunit Va 1.41
Oxidoreductase activity phosphoglycerate dehydrogenase 2.89
Oxidoreductase activity ferric-chelate reductase 1 1.34
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7.2 Plasmids and yeast strains generated
The plasmids used in the overexpression experiments were generated by isolating the
used genes and promoters using PCR, as described in section 6.2.2, and inserting
them into expression plasmids according to the ELIC protocol (Koskela and Frey,
2014), as described in section 6.2.3. Genes SBH1 and GPD2 were expressed under
their respective endogenous promoters. The two thioredoxins were expressed under
the TEF promoter, since thioredoxins are highly regulated, so their respective
promoters would probably include elements which would inactivate the genes in
various conditions. Thus to ensure their overexpression, the genes TRX1 and TRX2
were expressed under the strong, constitutive TEF promoter. The plasmids generated
in this study are mapped in pictures 10, 11, 12, and 13.
Figure 10: Plasmid pHI1, which includes the gene and promoter of SBH1, and LEU2
marker.
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Figure 11: Plasmid pHI2, which includes the gene and promoter of GPD2, and LEU2
marker.
Figure 12: Plasmid pHI3, which includes the gene TRX1, under TEF promoter and
LEU2 marker.
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Figure 13: Plasmid pHI4, which includes the gene TRX2 under TEF promoter, and
LEU2 marker.
Plasmid test digestion for pHI1, pHI3, and pHI4 is shown in figure 14. Since
the test digestion was unclear for plasmid pHI2, new colonies were screened and
test digested. The digestion is shown in picture 15. Protocol for test digestion is
described in section 6.2.3.
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Figure 14: Plasmid test digestion run on 1% agarose. The restriction enzymes
cut plasmid pHI1 into fragments of about 500 bp and 6000 bp, plasmid pHI3 into
fragments of about 2500 bp and 3500 bp, and plasmid pHI4 into fragments of about
300 and 6500 bp. Two colonies of each plasmid were tested for the correct insert,
and for pHI1, pHI3, and pHI4, the one on the right was chosen, respectively.
Figure 15: Plasmid test digestion run on 1% agarose. The chosen one is on the left,
and it is cut into one fragment of about 8000 bp.
The deletion strains were generated using homologous recombination with PCR
generated knockout cassettes, described in section 6.2.2. The cassettes, as well as
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the overexpression plasmids and pEK7 plasmids, were transformed into yeast by
LiAc transformation from liquid culture, according to the protocol in section 6.2.4.
The knockout yeasts YHI001-YHI004 were grown on YPD plates supplemented with
G418, which is selective for the kanMX marker in the knockout cassettes, as described
in section 6.2.5. Yeast strains YHI005-YHI013 were cultivated on SD-Leu plates, as
described in section 6.2.6. The yeast strains created in this study are listed in table
21. All yeast strains are based on YEK018 yeast strain, which is described in section
6.2. The plasmid pEK7 is described in section 6.2.4.
Table 21: Yeast strains generated in this thesis.
Yeast strain Description
YHI001 YEK018∆sbh1
YHI002 YEK018∆gpd2
YHI003 YEK018∆trx1
YHI004 YEK018∆trx2
YHI005 YEK018 with plasmid pHI1
YHI006 YEK018 with plasmid pHI2
YHI007 YEK018 with plasmid pHI3
YHI008 YEK018 with plasmid pHI4
YHI009 YHI001 with plasmid pEK7
YHI010 YHI002 with plasmid pEK7
YHI011 YHI003 with plasmid pEK7
YHI012 YHI004 with plasmid pEK7
YHI013 YEK018 with plasmid pEK7
7.3 Testing in vivo
The genes SBH1, GPD2, TRX1, and TRX2 were each overexpressed and knocked
out in antibody-secreting S. cerevisiae. The antibody secretion was induced by
galactose at four different concentrations; 0.5%, 1%, 2%, and 4%. The effects of the
overexpressions and knockouts on the secretion of the antibody were analysed by
ELISA. There were three rounds of ELISA, the first one had one plate, and the two
other were both conducted with two plates, thus in total there were five plates. On
one plate, there were two samples of each mutant yeast and two antibody-secreting
control yeasts per each galactose concentration.
Overall there was a lot of variation between different rounds of ELISA in the mea-
sured levels of antibody. The first round was done directly after the transformation,
so the yeasts had not been frozen. The last two rounds were done after re-striking
the frozen yeasts on new SD-Leu plates. In the first round of ELISA, the magnitude
of antibody concentration was 10−2mg/ml across all specimens, whereas in the last
round the magnitude was 10−3mg/ml. In the second round, i.e. plates 2 and 3, the
magnitude was 10−2mg/ml except the yeasts grown on 4% galactose concentration,
which the magnitude was 10−3mg/ml. Thus the freezing hindered the secretion of
the antibody. Freezing did not affect the OD600 values. The OD600 values did not
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correlate with whether the yeast strain was knock-out or overexpression yeast. In
order to minimize the bias arising from the differing antibody concentrations, four
diagrams were drawn:
• Concentration of antibody
• Antibody concentration relative to OD600 value
• Concentration of antibody relative to control yeast
• Concentration of antibody / OD600 value relative to control yeast
In the last two diagrams, the mean values of the control yeasts of each plate and
galactose concentration were set to 1, and the mutant yeast were compared to the
control yeasts on the same plate and the same galactose concentration, i.e. the yeasts
on plate one grown on 0.5% galactose were compared to the mean of the two control
yeasts grown on 0.5% on that plate. In all diagrams, cyan is yeast strain grown on
0.5% galactose, magenta on 1% galactose, green on 2% galactose, and yellow is yeast
strain grown on 4% galactose.
7.3.1 Sec61 beta subunit
SBH1 codes the beta subunit of the Sec61 complex involved in the uptake of the
nascent polypeptide chain into the lumen of the ER. The hypothesis was that its
overexpression would improve the uptake of the antibody into the ER, and hence
enhance the antibody secretion, but this did not happen. The bottleneck of the
antibody production therefore does not reside in the uptake of the nascent peptide
chains into the ER, or the uptake occurs via the Ssh1p complex described by Finke
et al. (1996). At the lowest galactose concentration (0.5%), the antibody secretion
was hindered by the overexpression of SBH1, but however at the 1% galactose
concentration the overexpression yeasts actually secreted more antibodies than their
control counterparts. This could be due because the bottleneck does not lie in the
step affected by the SBH1 gene.
The knockout didn’t effect the antibody secretion. This could mean that the
nascent polypeptide chain can be translocated into the ER via the Ssh1p complex.
The translocation into the ER could be further researched by the deletion and
overexpression of SBH2, which is the counterpart of SBH1 in the Ssh1p complex
(Finke et al., 1996). If its overexpression enhances the antibody secretion and
knockout hinders the secretion, it would indicate that the antibody is translocated
into the ER by the Ssh1p complex.
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Figure 16: The antibody concentration (µg/ml) of control and both the overexpression
and knockout SBH1 yeasts. The variety between different plates was large, hence
the big error margins.
Figure 17: The antibody concentration (µ/ml)/ODunit) of control and both the
overexpression and knockout SBH1 yeasts. The variety between different plates was
large, hence the big error margins. The overexpression of SBH1 lowered the antibody
secretion at the two lowest galactose concentrations. Knockout did not affect the
antibody secretion.
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Figure 18: The relative antibody concentration of both the overexpression and
knockout SBH1 yeasts compared to control yeasts on each respective plate. When
comparing the antibody concentration to the control yeasts on the same plate, the
knockout yeasts didn’t show any significant change in the level of secreted antibody.
The overexpression yeasts had lower antibody secretion at 0.5% galactose, but higher
at 1% galactose, and no significant changes at the two highest galactose consentrations.
Figure 19: The relative antibody concentration per OD unit of both the overexpression
and knockout SBH1 yeasts compared to control yeasts on each respective plate. When
compared to the control yeast on the same plate, the relative antibody concentration
was significantly lower in the overexpression yeast at 0.5% galactose.
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7.3.2 Glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
The expression of glycerol-3-phosphate dehydrogenase 2, GPD2, was downregulated
in plasma cells. In S. cerevisiae, it is the rate-controlling enzyme of the glycerol
formation pathway (Cronwright et al., 2002).
The overexpression of GPD2 slightly hindered the antibody secretion. It has
been noted by Cronwright et al. (2002) that the overexpression of GPD2 in S.
cerevisiae may reduce the concentration of ATP by redirecting carbon towards
glycerol formation pathway and away from the ATP-generating pathway. This could
also cause the lower secretion of antibody.
The knockout of GPD2 increased the relative antibody secretion, especially at
the two highest galactose concentrations, 2% and 4%. This could be due to higher
ATP concentration.
Figure 20: The antibody concentration (µg/ml) of control and both the overexpression
and knockout GPD2 yeasts. The variety between different plates was large, hence the
big error margins. The overexpression of GPD2 lowered the antibody concentration.
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Figure 21: The antibody concentration ((µ/ml)/ODunit) of control and both the
overexpression and knockout GPD2 yeasts. The variety between different plates was
large, hence the big error margins, especially in the knockout yeasts. The antibody
concentration per OD unit was lower in the overexpression yeasts than in the control
yeasts.
Figure 22: The relative antibody concentration of both the overexpression and
knockout GPD2 yeasts compared to control yeasts on each respective plate. The
antibody concentration compared to control yeasts was highest for knockout yeasts
at the two highest galactose concentrations. The overexpression of GPD2 hindered
the antibody secretion.
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Figure 23: The relative antibody concentration per OD unit of both the overexpression
and knockout GPD2 yeasts compared to control yeasts on each respective plate. The
antibody concentration per OD unit relative to control yeasts was lowest for the
overexpression yeasts at the lowest galactose concentration, and the highest for the
knockout yeasts at the two highest galactose concentrations.
7.3.3 Thioredoxin 1 and thioredoxin 2
There are two cytosolic thioredoxins in S. cerevisiae, which were studied separately.
Thioredoxins are required in the maintenance of the redox homeostasis in the cell
(Trotter and Grant, 2002). They also facilitate protein folding and enhance other
molecular chaperones in refolding activity. The thioredoxin fold of thioredoxins can
induce conformational changes in target disulphide by binding to target proteins
through backbone-backbone hydrogen bonds. This is followed by a nucleophilic
attack by a Cys-residue located in the N terminus of the fold.As a result, a mixed
disulfide covalent bond is generated. Thioredoxins also aid the folding activities of
other molecular chaperones (Berndt et al., 2008).
The overexpression of TRX1 hindered the secretion of the antibody, but the
overexpression of TRX2 increased it. It has been noted by Garrido and Grant (2002)
that TRX1 could have an auxiliary role to TRX2. The expression levels of the two
thioredoxins could be dependent of each other, and thus the overexpression of TRX1,
inhibits the expression of the more effective TRX2. As the overexpression of TRX2
increased the antibody secretion, it seems that the bottleneck in the production of
antibody in S. cerevisiae lies in the protein folding step, and the thioredoxin could
facilitate protein folding or help the maintenance of the redox homeostasis.
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Figure 24: The antibody concentration (µg/ml) of control and both the overexpression
and overexpression and knockout TRX1 yeasts. The variety between different plates
was large, hence the big error margins. The antibody secretion was lowered in
the overexpression yeasts, especially at the two highest galactose concentrations.
Knockout did not seem to affect the antibody secretion.
Figure 25: The antibody concentration ((µ/ml)/ODunit) of control and both the
overexpression and knockout TRX1 yeasts. The variety between different plates
was large, hence the big error margins. The overexpression of TRX1 lowered the
antibody concentration relative to OD units. Knockout didn’t affect the antibody
secretion per OD unit.
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Figure 26: The relative antibody concentration of both the overexpression and
knockout TRX1 yeasts compared to control yeasts on each respective plate. The
overexpression of TRX1 lowered the antibody secretion relative to control yeast,
however the error margins are large, especially for the yeasts grown on 0.5% galactose.
The knockout seemed to lower the antibody secretion on 1% galactose, but enhance
it on other concentrations.
Figure 27: The relative antibody concentration per OD unit of both the overexpression
and knockout TRX1 yeasts compared to control yeasts on each respective plate. The
overexpression of TRX1 lowered the antibody concentration per OD unit relative to
control yeast. The antibody secretion was hindered on all galactose concentrations.
The knockout lowered the relative antibody concentration per OD unit on 1%
galactose, but increased it on the other three galactose concentrations.
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Figure 28: The antibody concentration (µg/ml) of control and both the overexpression
and overexpression and knockout TRX2 yeasts. The variety between different plates
was large, and thus the error margins are large especially on the overexpression
yeasts grown on 0.5% galactose. The overexpression of TRX2 increased the antibody
concentration, and the knockout slightly hindered the secretion.
Figure 29: The antibody concentration ((µ/ml)/ODunit) of control and both the
overexpression and knockout TRX2 yeasts. The variety between different plates
was large, hence the big error margins. The overexpression of TRX2 increased the
antibody secretion relative to OD unit on the 0.5% galactose concentration.
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Figure 30: The relative antibody concentration of both the overexpression and
knockout TRX2 yeasts compared to control yeasts on each respective plate. Antibody
secretion relative to control yeasts was higher on the overexpression yeasts across all
galactose concentrations. The knockouts also had larger relative concentration of
antibody on 3% and 4% galactose, but the error margins are high.
Figure 31: The relative antibody concentration per OD unit of both the overexpression
and knockout TRX2 yeasts compared to control yeasts on each respective plate. The
overexpression of TRX2 increased the antibody concentration per OD unit relative
to control yeast. Also the knockout yeasts had increased antibody concentration per
OD unit on 3% and 4% galactose concentrations, but the error margins are very
large.
None of the genes selected for experiments in vivo had been tested in S. cerevisiae
regarding antibody production. It was found in a study by Toikkanen et al. (2003)
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that overexpressing SBH1 enhanced the production of α-amylase in S. cerevisiae.
In this study, a contradicting result was obtained, however as stated previously the
effects of modifications are specific to both the host and target protein. In a study
by Delic et al. (2014b) it was found that the overexpression of the gene encoding
transcription factor Yap1, which regulates the expression of both TRX1 and TRX2,
improved protein secretion in the yeast Pichia pastoris. No studies regarding the
effects of GPD2 on protein production in yeast were found.
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8 Conclusions and suggestions for future work
There are not yet any simple solutions on how to improve the production of proteins
in cell factories. Different host species and different target proteins require different
tactics for improving the product yield, as the bottleneck differs for each case. In this
thesis naïve B cells were compared with fully matured plasma cells in the enrichment
analysis in order to gain new ways to enhance the antibody production yield in S.
cerevisiae.
The bottleneck in the production of IgG antibody in S. cerevisiae seems to lie
in protein folding, as the overexpression of TRX2 enhanced the antibody secretion.
Further research could be aimed into the overexpression of other molecular chaperones
involved in folding activities. In the enrichment analysis there were 24 genes found
which had a homologue in S. cerevisiae. The 20 genes which were not studied in
vivo in this study could be overexpressed and knocked out in yeast. Additionally,
the mammalian genes which do not have a yeast homologue could be considered to
be expressed in yeast. Also other enriched terms than the ones chosen here could be
searched in order to find suitable candidates for genes to be expressed in yeast.
The results of the in vivo experiments showed that out of the genes tested, the
overexpression of TRX2 enhanced most the secretion of antibody in S. cerevisiae.
Thioredoxins are involved in the folding of antibodies, therefore the bottleneck in the
secretory pathway seems to be in the folding step. Also the results show that out of
the two thioredoxins tested, as it enhances the antibody secretion TRX2 seems to be
more involved in the folding of antibodies than the more auxiliary TRX1, either by
maintaining the redox homeostasis or by facilitating protein folding. As the knockout
of GPD2 improved IgG secretion, it could be combined with the overexpression
of TRX2 to see if further improved yield could be obtained. There was a lot of
variation in antibody concentration between different rounds of ELISA, possibly due
to freezing of the yeast strains. Even with the measures taken in this thesis to reduce
the variation, the error margins in the results are still high. This is still preliminary
data, and further reproduction of these experiments should reduce the variation.
Also, as the successful transformation of the knockouts were verified only by growing
on selective media, it is not completely sure if the transformations actually succeeded.
This thesis has shown that enrichment analysis provides useful information for
improving the protein yield of cell factories. However, as the processes inside the
cells are somewhat specific to species and in higher eukaryotes the type of cell, it is
not always possible to directly apply the results of enrichment analysis into other
type of cells. As this thesis has demonstrated, attempts to enhance the product
yield are still trial and error based. This could be overcome by collecting a database
from different studies, from which a researcher could search for suggested solutions
for the unique combination of produced protein and the host species. Most of the
enriched terms of plasma cells were involved in immunity, and not directly applicable
for transformations into S. cerevisiae. Additional information could be gained from
enrichment analysis comparing naïve B cells with developing plasma cells in different
stages of development. As the ways to enhance protein secretion are dependent of
species, cells of both wild type and antibody-secreting S. cerevisiae could be compared
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with each other, and overexpress the enriched genes of the antibody-secreting yeast.
Besides looking at transcriptomic data, enrichment analysis on proteomic data could
be conducted, and those results could be tested in vivo.
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A Gene enrichment analysis
#1 LOADING REQUIRED PACKAGES
install.packages("survival")
#this package is for downloading the data from GEO forming
#an ExpressionSet-object
source("http://bioconductor.org/biocLite.R")
biocLite("GEOquery")
require(GEOquery)
library(GEOquery)
#this package includes function that allow normalization of
#an ExpressionSet-object
biocLite("affyPLM")
require(affyPLM)
library(affyPLM)
#the annotation data
biocLite("illuminaHumanv4.db")
require(illuminaHumanv4.db)
biocLite("hugene10sttranscriptcluster.db")
library(hugene10sttranscriptcluster.db)
biocLite("hgu133a2.db")
library(hgu133a2.db)
biocLite("hgu133b.db")
library(hgu133b.db)
#this package is for enrichment analysis
biocLite("GOstats")
require(GOstats)
library(GOstats)
#fold change analysis package
biocLite("ELBOW")
library("ELBOW")
#for t-tests
require(genefilter)
biocLite("Rgraphviz")
#2 ANALYSIS OF DATA
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#Downloading data sets to R
#Cocco’s data
gset <- getGEO(filename= "GSE41208_series_matrix.txt", GSEMatrix =TRUE)
gset@annotation <- "illuminaHumanv4.db"
#filtering of data: removing probes without Entrez-ID
entrezIds <- mget(featureNames(gset), envir=illuminaHumanv4ENTREZID)
haveEntrezId <- names(entrezIds)[sapply(entrezIds, function(x) !is.na(x))]
gset.fil <- gset[haveEntrezId, ]
gset.fil@phenoData$STATUS #check if this is null, so can be utilized
#Mark the different experimental points
gstatus <- c(1,1,1,3,3,3,6,6,6,13,13,13,20,20,41,41,41,42,42,42,42)
gset.fil@phenoData$STATUS <- gstatus
#The expression data are marked by experimental point
CC1 <-gset.fil[, gset.fil@phenoData$STATUS%in%c(1,20)]
#comparing time point 0 with time point 20 d
CC2 <-gset.fil[, gset.fil@phenoData$STATUS%in%c(1,41)]
#comparing time point 0 with time point 41 d
CC3 <-gset.fil[, gset.fil@phenoData$STATUS%in%c(1,42)]
#comparing time point 0 with bone marrow plasma cells
#GO-enrichment analysis
#CC1
#Finding differentially expressed genes for GO-analysis
my.dataCC1 = exprs(CC1)
my.classes = c(1,1,1,20,20)
genenames = rownames(my.dataCC1)
ttestCutoff <- 0.0003
ttests = rowttests(my.dataCC1, factor(my.classes))
smPV = ttests$p.value < ttestCutoff
pvalFilteredCC1 <- my.dataCC1[smPV, ]
#Formatting data for fold change analysis
write.table(pvalFilteredCC1, file="ttestgenesCC1BP.csv", row.names=TRUE,
append=FALSE, sep=",")
csv_data <- read.table("ttestgenesCC1BP.csv", header=TRUE, sep=",", dec=".",
row.names=NULL)
init_count <- 3 #number of initial condition columns
final_count <- 2 #number of final condition columns
working_sets <- extract_working_sets(csv_data, init_count, final_count)
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probes <- working_sets[[1]]
initial_conditions <- working_sets[[2]]
final_conditions <- working_sets[[3]]
#Finding genes with significant fold change
sig <- analyze_elbow(probes, initial_conditions, final_conditions)
write.table(sig,file="signprobesCC1BP.csv",sep=",",row.names=FALSE,
append=FALSE)
write.table(sig$probe_names,file="signprobenamesCC1BP.csv",sep=",",
row.names=FALSE, col.names=FALSE, quote=FALSE, append=FALSE)
selectedgenesCC1BP <- readLines("signprobenamesCC1BP.csv")
selectedEntrezIds <- unlist(mget(selectedgenesCC1BP,illuminaHumanv4ENTREZID))
entrezUniverse <- unlist(mget(genenames,illuminaHumanv4ENTREZID))
#Parameters are set up for GO-enrichment testing
hgCutoff <- 0.00001
params <- new("GOHyperGParams", geneIds=selectedEntrezIds,
universeGeneIds=entrezUniverse,
annotation="illuminaHumanv4.db",
ontology="BP",
pvalueCutoff=hgCutoff,
conditional=TRUE,
testDirection="over")
#gives warning because of duplicates: removes them
#Enrichment test
hgOverCC1BP <- hyperGTest(params)
hgOverCC1BP
termListCC1BP <- summary(hgOverCC1BP)
termListCC1BP
htmlReport(hgOverCC1BP, file="hgOverCC1BP.html")
#two categories are tested for each differentiation state
#Finding differentially expressed genes for GO-analysis
ttestCutoff <- 0.001
smPV = ttests$p.value < ttestCutoff
pvalFilteredCC1 <- my.dataCC1[smPV, ]
#Formatting data for fold change analysis
write.table(pvalFilteredCC1, file="ttestgenesCC1MF.csv", row.names=TRUE,
append=FALSE, sep=",")
csv_data <- read.table("ttestgenesCC1MF.csv", header=TRUE, sep=",", dec=".",
row.names=NULL)
working_sets <- extract_working_sets(csv_data, init_count, final_count)
probes <- working_sets[[1]]
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initial_conditions <- working_sets[[2]]
final_conditions <- working_sets[[3]]
#Finding genes with significant fold change
sig <- analyze_elbow(probes, initial_conditions, final_conditions)
write.table(sig,file="signprobesCC1MF.csv",sep=",",row.names=FALSE,
append=FALSE)
write.table(sig$probe_names,file="signprobenamesCC1MF.csv", append=FALSE,
sep=",",row.names=FALSE, col.names=FALSE, quote=FALSE)
selectedgenesCC1MF <- readLines("signprobenamesCC1MF.csv")
selectedEntrezIds <- unlist(mget(selectedgenesCC1MF,illuminaHumanv4ENTREZID))
#Parameters are set up for GO-enrichment testing
hgCutoffMF <- 0.001
params <- new("GOHyperGParams", geneIds=selectedEntrezIds,
universeGeneIds=entrezUniverse,
annotation="illuminaHumanv4.db",
ontology="MF",
pvalueCutoff=hgCutoffMF,
conditional=TRUE,
testDirection="over")
#Enrichment test
hgOverCC1MF <- hyperGTest(params)
hgOverCC1MF
termListCC1MF <- summary(hgOverCC1MF)
termListCC1MF
htmlReport(hgOverCC1MF, file="hgOverCC1MF.html")
#Repeat the process for other data subsets
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B Differential expression
#LISTS OF DIFFERENTIALLY EXPRESSED GENES WITH THE LOWEST P-VALUES
#This function determines the differentially expressed genes with the lowest
#P-values.
#Inputs:
#data = gene expression data
#classes = experimental points
#ttestCutoff = cut-off value for rowttests function
#ann = annotation of data, as character, e.g. "illuminaHumanv4"
lowestPvalues <- function(data, classes, ttestCutoff, ann) {
ttests = rowttests(data, factor(classes))
smPV = ttests$p.value < ttestCutoff
pvalFiltered <- data[smPV, ]
selectedgenes = rownames(pvalFiltered)
namelist <- eval(parse(text=paste(c("mget(selectedgenes,", ann, "GENENAME)"),
collapse="")))
result <- as.matrix(namelist)
colnames(result, do.NULL = TRUE)
colnames(result) <- "Gene"
result
}
ttestCutoff <- 0.000002
my.classes = c(1,1,1,20,20)
namelistCC1 <- lowestPvalues(data = my.dataCC1, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "illuminaHumanv4")
my.classes = c(1,1,1,41,41,41)
namelistCC2 <- lowestPvalues(data = my.dataCC2, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "illuminaHumanv4")
my.classes = c(1,1,1,42,42,42,42)
namelistCC3 <- lowestPvalues(data = my.dataCC3, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "illuminaHumanv4")
my.classes = c(1,1,1,4,4,4)
namelistC1 <- lowestPvalues(data = my.dataC1, classes = my.classes,
ttestCutoff = ttestCutoff,
ann = "hugene10sttranscriptcluster")
ttestCutoff <- 0.0001
my.classes = c(1,1,4,4)
79
namelistGT1 <- lowestPvalues(data = my.dataGT1, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "hgu133a2")
ttestCutoff <- 0.000002
my.classes = c(rep((2),7),rep((4),3))
namelistA1 <- lowestPvalues(data = my.dataA1, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "hgu133a2")
my.classes = c(rep((2),7),rep((5),4))
namelistA2 <- lowestPvalues(data = my.dataA2, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "hgu133a2")
my.classes = c(rep((2),7),rep((4),3))
namelistA3 <- lowestPvalues(data = my.dataA3, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "hgu133b")
my.classes = c(rep((2),7),rep((5),4))
namelistA4 <- lowestPvalues(data = my.dataA4, classes = my.classes,
ttestCutoff = ttestCutoff, ann = "hgu133b")
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C termLists function
#This function compares the enriched GO-terms of each data subset
#Returns a table, where there is one GO-term in each row, and the columns
#show in which subsets the term appears in. Terms are arranged according to
#the number of enriched term lists they appear in.
#Inputs:
#tlist = list that contains sublists of enriched terms at different data subsets
#names = names of the data subsets in the order in which they appear in tlist
termLists <- function(tlist, names){
#An empty matrix for saving the results
result <- matrix(data = NA, nrow = 1000, ncol = length(tlist)+2)
dimnames(result) <- list(c(NULL), c("Genes", "Count",
paste("Termlist", 1:length(tlist),
sep="")))
for(i in 1:nrow(result)){ #Sets up a counter
result[i,2] = 0
i = i + 1
}
for(i in 1:length(tlist)) { #Goes through the gene lists one by one
x <- tlist[i] #Current gene list
terms <- tlist[[i]]$Term #Terms that appear in current gene list
id <- names[[i]] #The name of current gene list
for(j in 1:length(terms)) { #Goes through the term list one by one
for(k in 1:dim(result)[1]) {#Compares the terms to those in result matrix
matchFound = FALSE #This checks whether a match was found on the list
comparison <- terms[j] == result[k,1]
if(is.na(comparison)==TRUE) {
comparison=FALSE
}
if(comparison == TRUE){ #Checks for a match
matchFound = TRUE
for(m in 3:dim(result)[2]) {
if(is.na(result[k,m])==TRUE) {
#Saves the gene list id to the first available column
result[k,m]=id
break
} else {
m = m+1
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}
}
break
} else {
#If no match is found, checks the next term in the result matrix
k= k+1
}
}
if(matchFound==FALSE){
#If no matches were found, adds the term and gene list id to
#the first available spot in the result matrix
for(n in 1:dim(result)[1]) {
if(is.na(result[n,1])==TRUE) {
result[n,1]=terms[j]
result[n,3]=id
break
} else {
n = n+1
}
}
}
j = j+1 #Moves on to the next term
}
i = i+1 #Moves on to the next list
}
#Omit the NA rows from result matrix
matrixNA <- complete.cases(result[ ,1])
result2 <- result[matrixNA, ]
#Omit the NA columns from result matrix
countNA = 0
for(j in 1:ncol(result2)){
amountNA = sum(!is.na(result2[ ,j]))
empty <- amountNA == 0
if(empty == TRUE){
countNA = countNA + 1
j = j+1
} else {
j = j+1
}
}
firstDeletedColumn = ncol(result2)-countNA+1
result2 <- result2[,-c(firstDeletedColumn:ncol(result2))]
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#Counts the amount of lists in which each term appears
for(i in 1:nrow(result2)){
counter = sum(!is.na(result2[i, ]))-2
result2[i,2]=counter
i = i+1
}
#Arranges the rows
result4 <- transform.default(result2)
order.count <- order(result4$Count, decreasing=TRUE)
result5 <- result4[order.count, ]
}
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D extractGenes function
#This function checks which genes comprise the selected GO-term.
#It returns a table that has one gene in each row, and columns show in which
#subsets the gene appears in. If the GO-term is not enriched in a subset,
#it is not counted in the table. Genes are arranged according to the number
#of subsets they appear in.
#Parameters:
#tlist = list of GOHyperGResult objects
#selgenes = lists of genes used in GO-enrichment testing
#names = names of data subsets
#GOid = the GO ID of the selected GO-term
extractGenes <- function(tlist, selgenes, names, GOid){
lst <- list() #An empty list for saving the results
#Goes through the GOHyperGResult objects one by one and extracts their
#annotations
for(i in 1:length(tlist)) {
ann <- annotation(tlist[[i]])
#This function lists all Probe Set IDs associated with the selected
#Entrez IDs annotated at each significant GO term in the test result.
probes <- probeSetSummary(tlist[[i]], sigProbesets = selgenes[[i]],
ids = "ENTREZID")
selectedprobes <- probes[[GOid]] #All probes associated with GOid
empty <- is.null(selectedprobes)
if(all(empty) == FALSE) {
dname <- names[[i]] #Name of the current subset
#Extracts the names of the genes, creates a sublist for them
probeIds = selectedprobes[ ,2]
lst[[dname]] <- eval(parse(text=paste(c("mget(probeIds,", ann,
"GENENAME)"), collapse="")))
i = i+1 #Moves on to the next subset
} else { #If true, GOid was not enriched in the current subset
i = i+1
}
}
lst[sapply(lst, is.null)] <- NULL #Removes null elements
result <- geneLists(lst) #Calls geneLists function to final result format
result
}
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E geneLists function
#This function calculates the amount on data subsets that a gene appears in.
#It returns a table containing genes, the amount of data subsets they appear
#in, and the corresponding subsets.
#Inputs
#glist = a list containing sublists of genes that appear in specific
# data subsets
geneLists <- function(glist) {
resultLength = 0
for(i in 1:length(glist)){
resultLength = resultLength + length(glist[[i]])
}
#An empty matrix for saving the results
result <- matrix(data = NA, nrow = resultLength, ncol = 2+length(glist))
dimnames(result) <- list(c(NULL), c("Genes", "Amount of subsets",
paste("Genelist", 1:length(glist),
sep="")))
#Sets up the result matrix to contain the names of all genes in the lists
k = 1
for(i in 1:length(glist)) {
for(j in 1:length(glist[[i]])) {
gene <- as.character(glist[[i]][j])
result[k,1] = gene
k = k+1
j = j+1
}
i = i+1
}
for(i in 1:nrow(result)) { #Goes through the result matrix
for(j in 1:length(glist)) {
id = names(glist)[[j]] #Name of the current data subset
match = result[i,1]%in%glist[[j]]
if(match == TRUE){
j = j+1
for(m in 3:dim(result)[2]) {
if(is.na(result[i,m])==TRUE) {
#Saves the data subset name to the first available column
result[i,m]=id
break
} else {
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m = m+1
}
}
} else {
j = j+1 #Moves on to the next data subset
}
}
i = i+1 #Moves on to the next gene
}
result2 = unique(result) #Omits duplicate genes
#Counts the amount of data subsets in which each gene appears
for(i in 1:nrow(result2)){
counter = sum(!is.na(result2[i, ]))-1
result2[i,2]=counter
i = i+1
}
#Omits the NA columns from result matrix
countNA = 0
for(j in 1:ncol(result2)){
amountNA = sum(!is.na(result2[ ,j]))
empty <- amountNA == 0
if(empty == TRUE){
countNA = countNA + 1
j = j+1
} else {
j = j+1
}
}
firstDeletedColumn = ncol(result2)-countNA+1
if(firstDeletedColumn > ncol(result2)) {
result4 <- transform.default(result2)
} else {
result2 <- result2[,-c(firstDeletedColumn:ncol(result2))]
result4 <- transform.default(result2)
}
#Rearranges the rows so that in the first row is the gene that appears
#in the largest amount data subsets
order.count <- order(result4[ ,2], decreasing=TRUE)
result5 <- result4[order.count, ]
}
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F compareGeneLists function
#This function compares the differentially expressed genes and the genes
#associated with a certain GO-term. It returns a matrix where on each row
#there is a gene name (all genes are associated to the same GO-term), and
#the columns show in how many lists of differentially expressed genes
#the gene appears, in and the corresponding names of data subsets.
#It also tells in how many data subsets the gene was enriched.
#Inputs:
#genematrix = table of genes and data subsets in which they appear in
#(e.g. table returned by extractGenes function)
#diffList = a list where each sublist contains the list of most differentially
#expressed genes of a data subset
#names = names of data subsets in the order they appear in diffList
compareGeneLists <- function(genematrix, diffList, names) {
#An empty matrix for saving the results
result <- matrix(data = NA, nrow = length(genematrix[ ,1]),
ncol = 3+length(diffList))
dimnames(result) <- list(c(NULL), c("Genes", "Enrichment subsets",
"Differential expression subsets",
paste("Genelist", 1:length(diffList),
sep="")))
#Sets up the result matrix to contain the names of all genes associated
#with the GO term
for(i in 1:length(genematrix[ ,1])) {
gene <- as.character(genematrix[ ,1][i])
result[i,1] = gene
result[i,2] = as.character(genematrix[ ,2][i])
i = i+1
}
for(i in 1:nrow(result)) { #Goes through the result matrix
for(j in 1:length(diffList)) {
id = names[[j]] #Name of the list of differentially expressed genes
match = result[i,1]%in%diffList[[j]]
if(match == TRUE){
j = j+1
for(m in 4:dim(result)[2]) {
if(is.na(result[i,m])==TRUE) {
#Saves the gene list id to the first available column
result[i,m]=id
break
} else {
87
m = m+1
}
}
} else {
j = j+1
}
}
i = i+1
}
#Counts the amount of lists in which each gene appears
for(i in 1:nrow(result)){
counter = sum(!is.na(result[i, ]))-2
result[i,3]=counter
i = i+1
}
#Omit the NA columns from result matrix
countNA = 0
for(j in 1:ncol(result)){
amountNotNA = sum(!is.na(result[ ,j]))
empty <- amountNotNA == 0 #If a column is empty, number of non-NA rows is 0
if(empty == TRUE){ #True if an empty column is found
countNA = countNA + 1
j = j+1
} else {
j = j+1
}
}
firstDeletedColumn = ncol(result)-countNA+1
if(firstDeletedColumn > ncol(result)) {
result <- transform.default(result)
} else {
result <- result[,-c(firstDeletedColumn:ncol(result))]
result2 <- transform.default(result)
}
#Rearranges the rows so that in the first row is the gene that appears
#in the largest amount of lists of differentially expressed genes
order.count <- order(result2[ ,3], decreasing=TRUE)
result3 <- result2[order.count, ]
}
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G findFoldChange function
#This function finds the different fold changes of every gene in a list.
#It returns a table that has one gene in each row, and the fold changes
#in different data subsets in columns. It also calculates the mean and
#standard deviation of each gene’s fold change.
#Inputs:
#glist = the list of genes which fold changes need to be found out
#foldChanges = lists of fold changes
#names = list of names of the data subsets
#annotations = list of annotations of the data subsets as characters,
#e.g. "illuminaHumanv4"
findFoldChange <- function(glist, foldChanges, names, annotations) {
#An empty matrix for saving the results
result <- matrix(data = NA, nrow = length(glist[ ,1]),
ncol = 3+length(foldChanges))
dimnames(result) <- list(c(NULL), c("Gene", "Mean fold change",
"SD of fold change", names))
#these are for calculating each genes’ mean fold change and
#standard deviation
rowmean <- vector()
meanlist <- list()
#Sets up the result matrix to contain the names of all genes in
#the original list
for(i in 1:length(glist[ ,1])) {
gene <- as.character(glist[ ,1][i])
result[i,1] = gene
meanlist[[gene]] <- rowmean
i = i+1
}
for(j in 1:length(foldChanges)) {
#First find out the gene names of current foldChanges object
current <- read.table(file = foldChanges[[j]], header=TRUE, sep=",")
probeNames = as.character(current[ ,1])
#Extract the fold changes of current foldChanges object
fcs = as.numeric(current[, 2])
#the change is calculated from final to initial state, so
#multiply by -1 to get change from initial to final state
fcs = fcs*(-1)
ann = annotations[[j]]
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genenames <- eval(parse(text=paste(c("mget(probeNames,", ann,
"GENENAME)"), collapse="")))
fc <- matrix(data = NA, nrow = length(genenames), ncol=2)
#Matrix fc contains gene names and fold changes of
#the current foldChanges object
for(k in 1:length(genenames)){
fc[k,1] = as.character(genenames[[k]])
fc[k,2] = as.character(current[k,2])
k=k+1
}
for(i in 1:nrow(result)) { #Goes through the result matrix
#Finds out if there is a fold change for that gene
match = fc[ ,1]%in%result[i,1]
if(any(match) == TRUE){
if(is.null(dim(fc[match, ]))==TRUE) { #Only one match is found
fold <- fc[match, ][[2]]
meanlist[[i]] <- c(meanlist[[i]], as.numeric(fc[match, ][[2]]))
} else{ #Multiple matches
fold <- paste(fc[match, ][,2], collapse=", ")
meanlist[[i]] <- c(meanlist[[i]], as.numeric(fc[match,][,2]))
}
result[i,j+3] = fold #Saves the fold change to correct column
i = i+1
} else {
i = 1+1
}
}
j = j+1
}
#calculate mean fold change and standard deviation of each gene
for(i in 1:length(glist[ ,1])) {
mn <- mean(meanlist[[i]], na.rm = TRUE)
stdev <- sd(meanlist[[i]], na.rm = TRUE)
result[i,2] <- mn
result[i,3] <- stdev
}
result
}
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H Lists of the enriched GO-terms
Table H1: Enriched terms of A1 data subset consisting of cells from peripheral blood,
GO category biological process. The cutoff for P-value was 0.00001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0002429 0.000 4.825 8 31 180 immune response-activating cell surfacereceptor signaling pathway
GO:0050853 0.000 18.336 1 13 29 B cell receptor signaling pathway
GO:0002253 0.000 3.237 15 42 346 activation of immune response
GO:0051249 0.000 3.533 12 36 273 regulation of lymphocyte activation
GO:0002764 0.000 3.002 17 45 397 immune response-regulatingsignaling pathway
GO:0002696 0.000 3.916 9 31 214 positive regulation of leukocyteactivation
GO:0042113 0.000 4.222 8 27 174 B cell activation
GO:0050865 0.000 3.015 15 39 340 regulation of cell activation
GO:0030888 0.000 8.876 2 13 46 regulation of B cell proliferation
GO:0046651 0.000 3.802 8 27 190 lymphocyte proliferation
GO:0006955 0.000 2.025 49 86 1115 immune response
GO:0070661 0.000 3.578 9 27 200 leukocyte proliferation
GO:0050854 0.000 11.184 1 9 27 regulation of antigen receptor-mediatedsignaling pathway
GO:0050852 0.000 4.632 4 16 94 T cell receptor signaling pathway
GO:0002252 0.000 2.300 21 44 488 immune effector process
GO:0050870 0.000 3.532 7 21 156 positive regulation of T cell activation
GO:0048518 0.000 1.557 141 186 3246 positive regulation of biological process
GO:0002682 0.000 1.894 39 66 902 regulation of immune system process
GO:0048583 0.000 1.587 101 140 2319 regulation of response to stimulus
Table H2: Enriched terms of A1 data subset consisting of cells from peripheral blood,
GO categorymolecular function. The cutoff for P-value was 0.005
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0044822 0.000 1.714 60 94 914 poly(A) RNA binding
GO:0003714 0.000 2.629 11 26 169 transcription corepressor activity
GO:0000989 0.000 1.760 29 48 445 transcription factor binding transcriptionfactor activity
GO:0003677 0.001 1.392 106 137 1607 DNA binding
GO:0003676 0.001 1.491 67 92 1065 nucleic acid binding
GO:0003823 0.001 3.300 4 12 64 antigen binding
GO:0003682 0.001 1.875 20 35 305 chromatin binding
GO:0032395 0.001 14.207 1 4 8 MHC class II receptor activity
GO:0004896 0.002 2.860 5 13 78 cytokine receptor activity
GO:0070577 0.002 7.109 1 5 15 histone acetyl-lysine binding
GO:0042393 0.002 2.750 5 13 81 histone binding
GO:0043548 0.004 5.923 1 5 17 phosphatidylinositol 3-kinase binding
GO:0016303 0.004 8.116 1 4 11 1-phosphatidylinositol-3-kinase activity
GO:0004906 0.004 Inf 0 2 2 interferon-gamma receptor activity
GO:0034046 0.004 Inf 0 2 2 poly(G) binding
GO:0042610 0.004 Inf 0 2 2 CD8 receptor binding
GO:0003727 0.005 3.454 3 8 41 single-stranded RNA binding
91
Table H3: Enriched terms of A2 data subset consisting of cells from bone marrow,
GO category biological process. The cutoff for P-value was 0.000001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0002684 0.000 3.613 17 51 580 positive regulation of immune system process
GO:0002429 0.000 6.294 5 27 180 immune response-activating cell surfacereceptor signaling pathway
GO:0050853 0.000 24.248 1 12 29 B cell receptor signaling pathway
GO:0002253 0.000 3.922 10 34 346 activation of immune response
GO:0051251 0.000 5.139 6 25 197 positive regulation of lymphocyte activation
GO:0006955 0.000 2.514 33 69 1115 immune response
GO:0042113 0.000 5.359 5 23 174 B cell activation
GO:0002764 0.000 3.597 12 36 397 immune response-regulating signaling pathway
GO:0050867 0.000 4.647 7 26 224 positive regulation of cell activation
GO:0002694 0.000 3.940 9 31 312 regulation of leukocyte activation
GO:0006402 0.000 4.856 5 19 155 mRNA catabolic process
GO:0000184 0.000 6.156 3 15 99 nuclear-transcribed mRNA catabolic process,nonsense-mediated decay
GO:0045047 0.000 6.419 3 14 89 protein targeting to ER
GO:0019058 0.000 5.115 4 17 132 viral life cycle
GO:0030098 0.000 3.831 7 23 233 lymphocyte differentiation
GO:0042110 0.000 3.293 10 28 328 T cell activation
GO:0006414 0.000 6.557 2 13 81 translational elongation
GO:0030888 0.000 9.463 1 10 46 regulation of B cell proliferation
GO:0046651 0.000 4.090 6 20 190 lymphocyte proliferation
GO:0002252 0.000 2.751 14 35 488 immune effector process
Table H4: Enriched terms of A2 data subset consisting of cells from bone marrow,
GO categorymolecular function. The cutoff for P-value was 0.005
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0044822 0.000 2.440 44 91 833 poly(A) RNA binding
GO:0003735 0.000 5.623 6 25 107 structural constituent of ribosome
GO:0003676 0.000 1.565 142 192 2672 nucleic acid binding
GO:0019899 0.000 1.755 55 87 1030 enzyme binding
GO:0042393 0.000 3.355 5 15 96 histone binding
GO:0003779 0.001 2.053 16 30 297 actin binding
GO:0019901 0.001 1.974 18 33 339 protein kinase binding
GO:0030331 0.001 7.178 1 6 21 estrogen receptor binding
GO:0050733 0.001 26.812 0 3 5 RS domain binding
GO:0043548 0.002 7.466 1 5 17 phosphatidylinositol 3-kinase binding
GO:0008143 0.003 8.948 1 4 12 poly(A) binding
GO:0046625 0.003 8.948 1 4 12 sphingolipid binding
GO:0034988 0.003 Inf 0 2 2 Fc-gamma receptor I complex binding
GO:0042610 0.003 Inf 0 2 2 CD8 receptor binding
GO:0050072 0.003 Inf 0 2 2 m7G(5’)pppN diphosphatase activity
GO:0003682 0.003 1.838 16 28 305 chromatin binding
GO:0003729 0.004 2.830 4 11 81 mRNA binding
Table H5: Enriched terms of A3 data subset consisting of cells from peripheral blood,
GO category biological process. The cutoff for P-value was 0.0005
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0046649 0.000 3.026 8 22 174 lymphocyte activation
GO:0010829 0.000 40.317 0 4 6 negative regulation of glucose transport
GO:0070059 0.000 11.223 1 5 14 intrinsic apoptotic signaling pathway inresponse to endoplasmic reticulum stress
GO:0001775 0.000 2.223 13 27 281 cell activation
GO:0016574 0.000 10.099 1 5 15 histone ubiquitination
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Table H6: Enriched terms of A3 data subset consisting of cells from peripheral blood,
GO category molecular function. The cutoff for P-value was 0.01
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0035091 0.000 4.104 3 11 94 phosphatidylinositol binding
GO:0016881 0.001 2.922 5 14 163 acid-amino acid ligase activity
GO:0004842 0.001 3.033 5 13 146 ubiquitin-protein ligase activity
GO:0043325 0.002 18.092 0 3 8 phosphatidylinositol-3,4-bisphosphatebinding
GO:0004708 0.006 30.024 0 2 4 MAP kinase kinase activity
Table H7: Enriched terms of A4 data subset consisting of cells from bone marrow,
GO category biological process. The cutoff for P-value was 0.001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0045321 0.000 4.137 5 19 201 leukocyte activation
GO:0042113 0.000 7.077 2 10 64 B cell activation
GO:0045580 0.000 10.997 1 7 31 regulation of T cell differentiation
GO:0051252 0.000 1.985 38 61 1415 regulation of RNA metabolic process
GO:0010556 0.000 1.904 41 63 1517 regulation of macromolecule biosyntheticprocess
GO:0080090 0.000 1.812 56 79 2072 regulation of primary metabolic process
GO:0032774 0.000 1.863 41 63 1542 RNA biosynthetic process
GO:0030098 0.000 4.697 2 10 91 lymphocyte differentiation
GO:0051171 0.000 1.822 45 67 1687 regulation of nitrogen compoundmetabolic process
GO:0002764 0.000 3.370 5 14 174 immune response-regulatingsignaling pathway
GO:0090304 0.000 1.751 55 77 2053 nucleic acid metabolic process
GO:0006355 0.000 1.827 36 56 1361 regulation of transcription, DNA-templated
GO:0051249 0.000 4.174 3 10 101 regulation of lymphocyte activation
GO:0042110 0.000 3.811 3 11 121 T cell activation
GO:0002253 0.000 3.556 4 12 141 activation of immune response
GO:0031326 0.000 1.771 42 62 1570 regulation of cellular biosynthetic process
GO:0045727 0.000 9.319 1 5 25 positive regulation of translation
GO:0002684 0.001 2.933 6 15 212 positive regulation of immunesystem process
GO:0050865 0.001 3.642 3 11 126 regulation of cell activation
GO:1901362 0.001 1.711 46 65 1701 organic cyclic compoundbiosynthetic process
GO:0019438 0.001 1.715 45 64 1668 aromatic compound biosynthetic process
GO:0018130 0.001 1.713 45 64 1669 heterocycle biosynthetic process
GO:0039535 0.001 Inf 0 2 2 regulation of RIG-I signaling pathway
GO:0002683 0.001 4.567 2 8 74 negative regulation of immunesystem process
GO:0002429 0.001 4.498 2 8 75 immune response-activating cellsurface receptorn signaling pathway
GO:0065007 0.001 1.695 103 123 3851 biological regulation
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Table H8: Enriched terms of A4 data subset consisting of cells from bone marrow,
GO category molecular function. The cutoff for P-value was 0.01
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0003712 0.003 2.634 5 13 209 transcription cofactor activity
GO:0032266 0.003 12.812 0 3 12 phosphatidylinositol-3-phosphate binding
GO:0051059 0.003 12.812 0 3 12 NF-kappaB binding
GO:0005161 0.004 38.247 0 2 4 platelet-derived growth factor receptor binding
GO:0003823 0.005 10.479 0 3 14 antigen binding
GO:0000988 0.005 2.441 6 13 224 protein binding transcription factor activity
GO:0004716 0.006 25.494 0 2 5 receptor signaling protein tyrosinekinase activity
GO:0042393 0.007 4.500 1 5 48 histone binding
GO:0016796 0.009 8.230 0 3 17
exonuclease activity, active with either ribo- or
deoxyribonucleic acids and producing
5’-phosphomonoesters
GO:0042287 0.009 19.117 0 2 6 MHC protein binding
GO:0019900 0.010 2.416 5 11 190 kinase binding
Table H9: Enriched terms of CC1 data subset consisting of plasma cells grown for 20
days, GO category biological process. The cutoff for P-value was 0.00001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0002253 0.000 5.239 5 23 385 activation of immune response
GO:0006955 0.000 3.073 17 43 1270 immune response
GO:0002429 0.000 6.724 3 15 193 immune response-activating cell surfacereceptor signaling pathway
GO:0002764 0.000 4.276 6 22 442 immune response-regulating signaling pathway
GO:0002684 0.000 3.628 9 27 644 positive regulation of immune system process
GO:0042113 0.000 6.136 3 14 195 B cell activation
GO:0045321 0.000 3.553 8 25 603 leukocyte activation
GO:0050853 0.000 15.878 0 6 35 B cell receptor signaling pathway
GO:0051251 0.000 5.044 3 13 216 positive regulation of lymphocyte activation
GO:0048583 0.000 2.043 37 62 2767 regulation of response to stimulus
Table H10: Enriched terms of CC1 data subset consisting of plasma cells grown for
20 days, GO category molecular function. The cutoff for P-value was 0.001
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0019899 0.000 2.136 34 65 1195 enzyme binding
GO:0003735 0.000 4.680 4 17 145 structural constituent of ribosome
GO:0044822 0.000 2.099 32 60 1113 poly(A) RNA binding
GO:0019901 0.000 2.421 11 25 390 protein kinase binding
GO:0005488 0.001 1.572 343 369 12044 binding
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Table H11: Enriched terms of CC2 data subset consisting of plasma cells grown for
41 days, GO category biological process. The cutoff for P-value was 0.00002
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0001775 0.000 4.159 10 33 816 cell activation
GO:0006955 0.000 3.270 15 40 1270 immune response
GO:0042113 0.000 5.864 2 12 195 B cell activation
GO:0023051 0.000 2.213 28 51 2371 regulation of signaling
GO:0046649 0.000 4.464 3 14 315 lymphocyte activation
GO:0048583 0.000 2.100 32 56 2767 regulation of response to stimulus
GO:0010646 0.000 2.143 28 50 2378 regulation of cell communication
GO:0002429 0.000 5.372 2 11 193 immune response-activating cellsurface receptor signaling pathway
GO:0007165 0.000 1.939 52 78 4426 signal transduction
GO:0002520 0.000 3.480 6 18 489 immune system development
GO:0002694 0.000 3.977 4 15 355 regulation of leukocyte activation
Table H12: Enriched terms of CC2 data subset consisting of plasma cells grown for
41 days, GO category molecular function. The cutoff for P-value was 0.005
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0019899 0.000 2.304 19 40 1195 enzyme binding
GO:0019904 0.000 2.548 9 21 546 protein domain specific binding
GO:0004715 0.001 7.684 1 5 45 non-membrane spanning proteintyrosine kinase activity
GO:0019901 0.001 2.571 6 15 384 protein kinase binding
GO:0051434 0.002 60.868 0 2 4 BH3 domain binding
GO:0016773 0.002 2.080 11 22 692 phosphotransferase activity,alcohol group as acceptor
GO:0016301 0.002 2.019 12 23 745 kinase activity
GO:0008432 0.004 30.430 0 2 6 JUN kinase binding
GO:0055103 0.004 30.430 0 2 6 ligase regulator activity
GO:0043548 0.005 10.176 0 3 21 phosphatidylinositol 3-kinasebinding
GO:0003823 0.005 4.950 1 5 67 antigen binding
GO:0004674 0.005 2.260 7 15 430 protein serine/threonine kinaseactivity
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Table H13: Enriched terms of CC3 data subset consisting of cells from bone marrow,
GO category biological process. The cutoff for P-value was 0.000001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0034976 0.000 11.682 2 18 130 response to endoplasmic reticulum stress
GO:0035966 0.000 10.070 2 17 139 response to topologically incorrect protein
GO:0034620 0.000 13.699 1 14 87 cellular response to unfolded protein
GO:0006984 0.000 12.040 1 14 97 ER-nucleus signaling pathway
GO:0006987 0.000 14.909 1 11 63 activation of signaling protein activityinvolved in unfolded protein response
GO:0032069 0.000 12.914 1 11 71 regulation of nuclease activity
GO:0018279 0.000 10.218 1 12 95 protein N-linked glycosylation viaasparagine
GO:0070972 0.000 8.302 2 13 124 protein localization to endoplasmicreticulum
GO:0044267 0.000 2.205 50 85 3389 cellular protein metabolic process
GO:0002478 0.000 6.543 2 14 166 antigen processing and presentation ofexogenous peptide antigen
GO:0019882 0.000 5.525 3 16 223 antigen processing and presentation
GO:0006488 0.000 17.950 0 7 34 dolichol-linked oligosaccharide biosyntheticprocess
GO:0030433 0.000 16.152 1 7 37 ER-associated ubiquitin-dependent proteincatabolic process
Table H14: Enriched terms of CC3 data subset consisting of cells from bone marrow,
GO category molecular function. The cutoff for P-value was 0.0001
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0004579 0.000 140.560 0 7 8 dolichyl-diphosphooligosaccharide-proteinglycotransferase activity
GO:0003954 0.000 9.240 2 11 35 NADH dehydrogenase activity
GO:0008137 0.000 9.240 2 11 35 NADH dehydrogenase (ubiquinone)activity
GO:0016758 0.000 3.203 9 25 184 transferase activity, transferring hexosylgroups
GO:0032395 0.000 24.055 1 6 11 MHC class II receptor activity
GO:0016655 0.000 5.830 2 11 49 oxidoreductase activity, acting on NAD(P)H,quinone or similar compound as acceptor
GO:0016491 0.000 1.890 33 57 680 oxidoreductase activity
GO:0003756 0.000 12.024 1 6 16 protein disulfide isomerase activity
Table H15: Enriched terms of C1 data subset consisting of plasmablasts, GO category
biological process. The cutoff for P-value was 0.001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0002684 0.000 2.516 9 21 631 positive regulation of immune systemprocess
GO:0036092 0.000 29.784 0 3 10 phosphatidylinositol-3-phosphatebiosynthetic process
GO:0045017 0.000 3.756 3 11 220 glycerolipid biosynthetic process
GO:0007067 0.000 3.058 5 14 343 mitosis
GO:0030071 0.001 8.336 1 5 47 regulation of mitotic metaphase/anaphasetransition
GO:0007079 0.001 138.352 0 2 3 mitotic chromosome movement towardsspindle pole
GO:0006955 0.001 1.998 18 32 1224 immune response
GO:0030888 0.001 7.291 1 5 53 regulation of B cell proliferation
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Table H16: Enriched terms of C1 data subset consisting of plasmablasts, GO category
molecular function. The cutoff for P-value was 0.005
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0043813 0.000 Inf 0 2 2 phosphatidylinositol-3,5-bisphosphate5-phosphatase activity
GO:0034596 0.001 70.890 0 2 4 phosphatidylinositol phosphate4-phosphatase activity
GO:0000099 0.003 35.440 0 2 6 sulfur amino acid transmembranetransporter activity
GO:0015175 0.003 11.861 0 3 21 neutral amino acid transmembranetransporter activity
GO:0019899 0.003 1.857 16 28 1159 enzyme binding
GO:0016308 0.004 28.350 0 2 7 1-phosphatidylinositol-4-phosphate5-kinase activity
GO:0043014 0.004 10.164 0 3 24 alpha-tubulin binding
Table H17: Enriched terms of GT1 data subset consisting of cells from spleen, GO
category biological process. The cutoff for P-value was 0.0001
GOBPID Pvalue OddsRatio ExpCount Count Size Term
GO:0006955 0.000 2.738 15 35 1115 immune response
GO:0051251 0.000 5.466 3 13 197 positive regulation of lymphocyte activation
GO:0042110 0.000 4.008 5 16 328 T cell activation
GO:0050867 0.000 4.754 3 13 224 positive regulation of cell activation
GO:0031295 0.000 10.097 1 7 59 T cell costimulation
GO:0002429 0.000 4.969 2 11 180 immune response-activating cell surfacereceptor signaling pathway
GO:0060333 0.000 8.600 1 7 68 interferon-gamma-mediated signalingpathway
GO:0002694 0.000 3.622 4 14 312 regulation of leukocyte activation
Table H18: Enriched terms of GT1 data subset consisting of cells from spleen, GO
category molecular function. The cutoff for P-value was 0.01
GOMFID Pvalue OddsRatio ExpCount Count Size Term
GO:0003823 0.000 12.684 1 9 64 antigen binding
GO:0032395 0.000 44.765 0 3 8 MHC class II receptor activity
GO:0032403 0.002 2.358 8 17 582 protein complex binding
GO:0023026 0.006 21.165 0 2 9 MHC class II protein complex binding
GO:0003746 0.009 16.458 0 2 11 translation elongation factor activity
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I Differentially expressed genes
Table I1: The most differentially expressed genes of subset A1. P-value cutoff was
1−8
B-cell translocation gene 1, anti-proliferative
B-cell translocation gene 1, anti-proliferative
actin binding LIM protein 1
major histocompatibility complex, class II, DP beta 1
ribosome binding protein 1
synaptophysin-like 1
kelch-like ECH-associated protein 1
trafficking protein particle complex 12
nucleobindin 2
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
major histocompatibility complex, class II, DM beta
cyclin-dependent kinase 5
hematopoietically expressed homeobox
lymphotoxin beta (TNF superfamily, member 3)
TSC22 domain family, member 3
Wolf-Hirschhorn syndrome candidate 1
UDP-N-acteylglucosamine pyrophosphorylase 1
T-cell leukemia/lymphoma 1A
chemokine (C-X-C motif) receptor 4
ER membrane protein complex subunit 1
septin 7
tripartite motif containing 22
elongation factor, RNA polymerase II, 2
CD72 molecule
hematopoietically expressed homeobox
membrane-spanning 4-domains, subfamily A, member 1
5’-nucleotidase domain containing 2
phosphopantothenoylcysteine decarboxylase
SLAM family member 7
ninjurin 2
aquaporin 3 (Gill blood group)
T-cell leukemia/lymphoma 1A
98
Table I2: The most differentially expressed genes of subset A2. P-value cutoff was
1−8
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2
cytoskeleton-associated protein 4
signal sequence receptor, delta
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A
major histocompatibility complex, class II, DP beta 1
peroxiredoxin 4
peptidylglycine alpha-amidating monooxygenase
hematopoietic cell-specific Lyn substrate 1
metastasis suppressor 1
trafficking protein particle complex 12
TIMP metallopeptidase inhibitor 2
interleukin 4 receptor
nucleobindin 2
inositol 1,4,5-trisphosphate receptor, type 1
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
major histocompatibility complex, class II, DM beta
interferon regulatory factor 8
CD37 molecule
selectin L
CD22 molecule
interferon (alpha, beta and omega) receptor 2
CD19 molecule
lymphocyte antigen 96
family with sequence similarity 65, member B
lymphotoxin beta (TNF superfamily, member 3)
RAS guanyl releasing protein 2 (calcium and DAG-regulated)
tumor necrosis factor, alpha-induced protein 8
DnaJ (Hsp40) homolog, subfamily C, member 3
dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit (non-catalytic)
major histocompatibility complex, class II, DR alpha
transmembrane 9 superfamily member 1
UDP-N-acteylglucosamine pyrophosphorylase 1
phospholipase A2, group XVI
SEPT5-GP1BB readthrough
CD69 molecule
family with sequence similarity 65, member B
membrane-spanning 4-domains, subfamily A, member 1
sorting nexin 3
major histocompatibility complex, class II, DR alpha
immunoglobulin lambda constant 1 (Mcg marker)
lamin A/C
protein tyrosine phosphatase, receptor type, C
protein tyrosine phosphatase, receptor type, C
immunoglobulin heavy constant mu
tripartite motif containing 22
insulin receptor
nucleosome assembly protein 1-like 1
elongation factor, RNA polymerase II, 2
CD72 molecule
hematopoietically expressed homeobox
immunoglobulin lambda-like polypeptide 3, pseudogene
ring finger protein 5, E3 ubiquitin protein ligase
microtubule associated serine/threonine kinase 1
membrane-spanning 4-domains, subfamily A, member 1
major histocompatibility complex, class II, DM alpha
nicotinamide phosphoribosyltransferase
proline-rich nuclear receptor coactivator 2
ubiquitin-conjugating enzyme E2, J1
5’-nucleotidase domain containing 2
signal recognition particle receptor, B subunit
ubiquitin-like modifier activating enzyme 5
SIL1 nucleotide exchange factor
FK506 binding protein 11, 19 kDa
SLAM family member 7
BTB and CNC homology 1, basic leucine zipper transcription factor 2
transmembrane protein 208
Fas apoptotic inhibitory molecule 3
Fas apoptotic inhibitory molecule 3
chromosome 19 open reading frame 10
capping protein (actin filament) muscle Z-line, beta
CD22 molecule
aquaporin 3 (Gill blood group)
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Table I3: The most differentially expressed genes of subset A3. P-value cutoff was
1−7
peptidylprolyl isomerase (cyclophilin)-like 1
DnaJ (Hsp40) homolog, subfamily C, member 1
solute carrier family 35 (GDP-fucose transporter), member C1
B-cell CLL/lymphoma 11A (zinc finger protein)
KIAA1147
v-ets avian erythroblastosis virus E26 oncogene homolog 1
forkhead box P1
forkhead box P1
homeodomain interacting protein kinase 2
pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2
TSEN15 tRNA splicing endonuclease subunit
phosphoprotein associated with glycosphingolipid microdomains 1
ankyrin repeat domain 28
zinc finger, CCHC domain containing 7
La ribonucleoprotein domain family, member 1B
hydrogen voltage-gated channel 1
centromere protein W
AF4/FMR2 family, member 3
membrane-spanning 4-domains, subfamily A, member 1
membrane-spanning 4-domains, subfamily A, member 1
membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase
family with sequence similarity 26, member F
T-cell activation RhoGTPase activating protein
long intergenic non-protein coding RNA 926
baculoviral IAP repeat containing 3
Fc receptor-like 3
immunoglobulin lambda variable 1-44
tetratricopeptide repeat domain 39C
Fc receptor-like 1
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Table I4: The most differentially expressed genes of subset A4. P-value cutoff was
1−7
signal sequence receptor, gamma (translocon-associated protein gamma)
peptidylprolyl isomerase (cyclophilin)-like 1
DnaJ (Hsp40) homolog, subfamily C, member 1
DnaJ (Hsp40) homolog, subfamily C, member 1
regulatory factor X, 7
fucosidase, alpha-L- 2, plasma
VCP-interacting membrane protein
forkhead box P1
dystrobrevin binding protein 1
kidney associated antigen 1
cytochrome b561 family, member A3
v-ets avian erythroblastosis virus E26 oncogene homolog 1
forkhead box P1
forkhead box P1
scavenger receptor class B, member 2
pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2
collagen triple helix repeat containing 1
v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog K
zinc finger, CCHC domain containing 7
major histocompatibility complex, class II, DO alpha
hydrogen voltage-gated channel 1
elongation factor, RNA polymerase II, 2
AF4/FMR2 family, member 3
transmembrane anterior posterior transformation 1
protein kinase C, beta
napsin B aspartic peptidase, pseudogene
calcium/calmodulin-dependent protein kinase II delta
membrane-spanning 4-domains, subfamily A, member 1
ubiquitin-conjugating enzyme E2, J1
ITGB2 antisense RNA 1
ankyrin repeat domain 28
ribosomal modification protein rimK-like family member B
membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase
family with sequence similarity 26, member F
DENN/MADD domain containing 6B
forkhead box P1
meiosis inhibitor 1
long intergenic non-protein coding RNA 926
family with sequence similarity 129, member C
mucin 17, cell surface associated
myosin, heavy chain 7B, cardiac muscle, beta
immunoglobulin lambda variable cluster
NLR family, CARD domain containing 3
CASP8 and FADD-like apoptosis regulator
CD53 molecule
Fc receptor-like 1
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Table I5: The most differentially expressed genes of subset CC1. P-value cutoff was
1−5
phosphoinositide-3-kinase adaptor protein 1
Fc receptor-like 2
von Willebrand factor A domain containing 5A
coatomer protein complex, subunit beta 2 (beta prime)
FYN oncogene related to SRC, FGR, YES
chemokine (C-C motif) receptor 6
quinolinate phosphoribosyltransferase
ALG3, alpha-1,3- mannosyltransferase
met proto-oncogene
apolipoprotein O
nucleobindin 1
translocation associated membrane protein 1
eukaryotic translation initiation factor 3, subunit D
kynureninase
lipocalin-like 1
DnaJ (Hsp40) homolog, subfamily B, member 11
hematopoietically expressed homeobox
neurensin 2
thioredoxin domain containing 11
Fas apoptotic inhibitory molecule 3
baculoviral IAP repeat containing 3
T-cell leukemia/lymphoma 1A
proteolipid protein 1
androgen-induced 1
psoriasis susceptibility 1 candidate 1
adenosine deaminase
lectin, galactoside-binding, soluble, 3
ankyrin repeat and SOCS box containing 16
non-POU domain containing, octamer-binding
SEC24 family member A
regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2
lymphoblastic leukemia associated hematopoiesis regulator 1
glutamine–fructose-6-phosphate transaminase 1
CD38 molecule
integrin, alpha 6
Sec23 homolog B (S. cerevisiae)
Sec61 gamma subunit
lymphotoxin beta (TNF superfamily, member 3)
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
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Table I6: The most differentially expressed genes of subset CC2. P-value cutoff was
1−6
major histocompatibility complex, class II, DO alpha
signal sequence receptor, delta
dipeptidase 2
growth arrest and DNA-damage-inducible, alpha
kynureninase
serglycin
hematopoietically expressed homeobox
tyrosyl-tRNA synthetase
pelota homolog (Drosophila)
chromosome 8 open reading frame 48
FK506 binding protein 11, 19 kDa
T-cell leukemia/lymphoma 1A
CDGSH iron sulfur domain 2
psoriasis susceptibility 1 candidate 1
ankyrin repeat and SOCS box containing 16
RAS guanyl releasing protein 2 (calcium and DAG-regulated)
lymphotoxin beta (TNF superfamily, member 3)
membrane-spanning 4-domains, subfamily A, member 1
PR domain containing 1, with ZNF domain
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Table I7: The most differentially expressed genes of subset CC3. P-value cutoff was
1−6
sphingosine-1-phosphate receptor 1
major histocompatibility complex, class II, DO alpha
B-cell scaffold protein with ankyrin repeats 1
RIC8 guanine nucleotide exchange factor B
family with sequence similarity 129, member C
BTB and CNC homology 1, basic leucine zipper transcription factor 2
lysosomal-associated membrane protein 2
FK506 binding protein 2, 13kDa
GRB2-binding adaptor protein, transmembrane
phosphohistidine phosphatase 1
signal sequence receptor, delta
SMAD family member 3
FYN oncogene related to SRC, FGR, YES
v-ets avian erythroblastosis virus E26 oncogene homolog 1
chemokine (C-C motif) receptor 6
small integral membrane protein 7
chemokine (C-C motif) receptor 7
histone cluster 1, H2bg
MOB kinase activator 3B
CD72 molecule
ADP-ribosylation factor 4
family with sequence similarity 65, member B
TNF receptor-associated factor 5
kynureninase
hematopoietically expressed homeobox
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2
KIAA0226-like
GDP-mannose pyrophosphorylase B
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)
AF4/FMR2 family, member 3
membrane-spanning 4-domains, subfamily A, member 1
tripartite motif containing 22
WD repeat domain, phosphoinositide interacting 1
chromosome 19 open reading frame 10
T-cell leukemia/lymphoma 1A
G protein-coupled receptor 132
methyltransferase like 1
BTB and CNC homology 1, basic leucine zipper transcription factor 2
metastasis suppressor 1
membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase
napsin B aspartic peptidase, pseudogene
mesencephalic astrocyte-derived neurotrophic factor
CD38 molecule
chemokine (C-X-C motif) receptor 5
ATP-binding cassette, sub-family B (MDR/TAP), member 9
RAS guanyl releasing protein 2 (calcium and DAG-regulated)
lymphotoxin beta (TNF superfamily, member 3)
lymphotoxin beta (TNF superfamily, member 3)
CD247 molecule
membrane-spanning 4-domains, subfamily A, member 1
guanine nucleotide binding protein (G protein), beta 5
sphingosine-1-phosphate receptor 1
transmembrane protein 208
immunoglobulin kappa variable 1/ORY-1 (pseudogene)
signal peptidase complex subunit 3 homolog (S. cerevisiae)
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Table I8: The most differentially expressed genes of subset C1. P-value cutoff was
1−6
decapping enzyme, scavenger
signal transducer and activator of transcription 6, interleukin-4 induced
chromosome 12 open reading frame 42
T-cell leukemia/lymphoma 1A
phosphopantothenoylcysteine decarboxylase
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B
fibronectin type III domain containing 3B
selenoprotein K
guanine nucleotide binding protein (G protein), beta polypeptide 4
leucine aminopeptidase 3
SEC24 family member D
SEC24 family member A
PR domain containing 1, with ZNF domain
phosphoserine aminotransferase 1
solute carrier family 44 (choline transporter), member 1
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)
Table I9: The most differentially expressed genes of subset GT1. P-value cutoff was
1−4
signal sequence receptor, alpha
cytochrome c-1
SWAP switching B-cell complex 70kDa subunit
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
major histocompatibility complex, class II, DP alpha 1
immunoglobulin kappa constant
dystonin
zinc finger protein 419
SH3-domain binding protein 4
ribokinase
